Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
47.1 /100
Rank 8 out of 27 Sectors -
Advance/Decline
181/480
-
No. of Companies661
-
Avg. Market Cap7,067
-
Price to Earning Ratio6.29
-
Price to Earning Growth Ratio0.65
-
Price to Book Ratio24.34
-
Return on Equity46.89
-
Return on Capital Employed-
-
Return on Assets10.63
-
Dividend yield 1 year %0.83 %
-
Net Profit Growth Annual YoY %-12.26 %
-
Net Profit Growth Qtr YoY %38.63 %
-
Net Profit Growth Qtr QoQ %613.01 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
374,439.7
|
212.0
|
L
 -2.8%
H
211.7
219
|
L
 -7.0%
H
211.7
229.7
|
L
 -10.4%
H
211.7
238.8
|
L
 8.6%
H
193.7
244.8
|
L
 4.1%
H
163.8
244.8
|
L
 46.7%
H
131.0
244.8
|
L
 140.2%
H
87.4
244.8
|
L
 234.4%
H
50.7
244.8
|
| Adc Therapeutics SA |
|
470.2
|
4.2
|
L
 -6.3%
H
4.1
4.4
|
L
 2.2%
H
4.1
4.8
|
L
 5.0%
H
3.9
4.8
|
L
 55.4%
H
2.6
4.8
|
L
 41.7%
H
1.1
4.8
|
L
 1.2%
H
0.4
6.0
|
L
 -85.6%
H
0.4
38.3
|
L
H
0.4
56.6
|
| Amneal Pharmaceuticals Inc |
|
3,517.7
|
11.2
|
L
 3.5%
H
10.7
11.2
|
L
 6.2%
H
10.0
11.2
|
L
 7.7%
H
9.6
11.2
|
L
 43.0%
H
7.8
11.2
|
L
 31.9%
H
6.7
11.2
|
L
 430.8%
H
1.2
11.2
|
L
 150.6%
H
1.2
11.2
|
L
 -68.1%
H
1.2
45
|
| Annovis Bio Inc |
|
47.1
|
2.0
|
L
 -3.8%
H
2.0
2.1
|
L
 -1.5%
H
2.0
2.3
|
L
 -9.4%
H
1.6
2.6
|
L
 -19.5%
H
1.6
3.0
|
L
 -77.8%
H
1.1
9.2
|
L
 -84.5%
H
1.1
23.9
|
L
 -53.7%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,523.2
|
6.8
|
L
 -3.0%
H
6.8
7.1
|
L
 9.8%
H
5.9
7.2
|
L
 4.0%
H
5.9
7.2
|
L
 19.3%
H
5.6
8.7
|
L
 -30.4%
H
4.3
9.9
|
L
 4.3%
H
4.0
11.5
|
L
 -60.7%
H
4.0
34.8
|
L
 -93.2%
H
4.0
119.9
|
| Bristol-Myers Squibb |
|
93,685.4
|
46.0
|
L
 -0.1%
H
45.5
46.7
|
L
 5%
H
42.5
46.7
|
L
 2.0%
H
42.5
46.7
|
L
 4.1%
H
42.5
49.6
|
L
 -15.3%
H
42.5
63.3
|
L
 -40.6%
H
39.4
81.4
|
L
 -22.6%
H
39.4
81.4
|
L
 -30.0%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
550.9
|
10.5
|
L
 -16.0%
H
10.2
12.7
|
L
 7.7%
H
9.2
13.4
|
L
 14.2%
H
8.9
13.4
|
L
 86.3%
H
5.6
13.4
|
L
 15.0%
H
4.0
13.4
|
L
 -47.8%
H
1.4
20.5
|
L
 -88.5%
H
1.4
127.2
|
L
 -66.5%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,352.2
|
22.9
|
L
 3.2%
H
21.9
23.0
|
L
 3.6%
H
21.8
23.0
|
L
 11.6%
H
19.5
23.0
|
L
 65.7%
H
13.8
23.0
|
L
 81.4%
H
8.0
23.0
|
L
 73.8%
H
7.9
23.0
|
L
 -28.2%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK Plc ADR |
|
93,122.0
|
46.4
|
L
 -1.1%
H
46.3
46.8
|
L
 7.2%
H
42.9
47.2
|
L
 6.1%
H
42.8
47.2
|
L
 23.4%
H
36.8
47.2
|
L
 25.7%
H
31.7
47.2
|
L
 39.9%
H
31.2
47.2
|
L
 32.4%
H
28.5
47.8
|
L
 5.6%
H
28.5
49.1
|
| Johnson & Johnson |
|
448,755.3
|
186.3
|
L
 -1.4%
H
185.5
189.0
|
L
 -2.2%
H
184.7
190.8
|
L
 0.2%
H
182.9
194.5
|
L
 11.3%
H
166.6
194.5
|
L
 16.3%
H
140.7
194.5
|
L
 9.3%
H
140.7
194.5
|
L
 34.3%
H
137.8
194.5
|
L
 82.3%
H
94.3
194.5
|
| Eli Lilly |
|
802,411.2
|
896.5
|
L
 3.9%
H
862.6
901.3
|
L
 8.6%
H
809.6
901.3
|
L
 9.4%
H
783.8
901.3
|
L
 17.6%
H
623.8
901.3
|
L
 9.5%
H
623.8
935.6
|
L
 152.6%
H
302.1
972.5
|
L
 581.1%
H
130.7
972.5
|
L
 992.8%
H
64.2
972.5
|
| Merck & Company |
|
206,042.1
|
82.5
|
L
 -4.1%
H
82.3
86.1
|
L
 -5.7%
H
82.3
88.3
|
L
 -7.8%
H
82.3
90.7
|
L
 4.0%
H
77.6
91
|
L
 -19.0%
H
73.3
105.1
|
L
 -17.0%
H
73.3
134.6
|
L
 12.7%
H
68.4
134.6
|
L
 56.9%
H
45.8
134.6
|
| Nuvation Bio Inc Ordinary |
|
1,769.5
|
5.2
|
L
 -1.0%
H
5.1
5.4
|
L
 6.6%
H
4.8
5.6
|
L
 39.4%
H
3.4
5.6
|
L
 131.8%
H
2.2
5.6
|
L
 124.8%
H
1.5
5.6
|
L
 138.2%
H
1.0
5.6
|
L
 -48.6%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk ADR |
|
218,216.8
|
49.1
|
L
 -0.7%
H
48.6
49.5
|
L
 -7.3%
H
48.5
53.2
|
L
 -16.4%
H
48.5
60.9
|
L
 1.9%
H
45.1
62.3
|
L
 -56.1%
H
45.1
112.5
|
L
 -13.3%
H
45.1
148.2
|
L
 51.0%
H
32.6
148.2
|
L
 83.0%
H
15.5
148.2
|
| Novartis AG ADR |
|
237,661.6
|
123.9
|
L
 0.1%
H
122.9
124.1
|
L
 -5.0%
H
121.6
130.2
|
L
 -5.4%
H
121.6
133.6
|
L
 7.4%
H
113.5
133.6
|
L
 13.3%
H
96.1
133.6
|
L
 53.7%
H
79.8
133.6
|
L
 55.3%
H
74.1
133.6
|
L
 53.9%
H
59.2
133.6
|
| Organon Co |
|
1,744.4
|
6.7
|
L
 -0.6%
H
6.5
6.9
|
L
 -26.8%
H
6.2
7.6
|
L
 -38.7%
H
6.2
11.3
|
L
 -31.2%
H
6.2
11.3
|
L
 -62.9%
H
6.2
18.0
|
L
 -74.1%
H
6.2
32.4
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare |
|
2,981.4
|
60.6
|
L
 0.0%
H
59.6
60.9
|
L
 -2.7%
H
59.6
62.8
|
L
 -3.6%
H
59.6
64.3
|
L
 -17.8%
H
59.6
75.3
|
L
 -18.2%
H
59.6
90.0
|
L
 11.6%
H
52
90.0
|
L
 80.3%
H
32.9
90.0
|
L
 22.8%
H
26.3
90.0
|
| Pfizer |
|
140,205.7
|
24.7
|
L
 0.0%
H
24.4
24.8
|
L
 -0.4%
H
24.2
24.8
|
L
 -8.9%
H
24.2
27.7
|
L
 5.0%
H
23.4
27.7
|
L
 -12.2%
H
20.9
28.1
|
L
 -47.6%
H
20.9
54.9
|
L
 -28.1%
H
20.9
61.7
|
L
 -25.7%
H
20.9
61.7
|
| Perrigo Company plc |
|
2,824.6
|
20.5
|
L
 -1.0%
H
20.3
20.7
|
L
 -4.3%
H
20.3
22.0
|
L
 -7.3%
H
20.3
22.7
|
L
 -22.9%
H
20.3
27.2
|
L
 -21.3%
H
20.3
30.9
|
L
 -48.3%
H
20.3
40.3
|
L
 -55.0%
H
20.3
50.9
|
L
 -87.1%
H
20.3
165.6
|
| Arcus Biosciences Inc |
|
2,197.3
|
20.4
|
L
 3.2%
H
19.7
20.7
|
L
 17.6%
H
17.5
22.1
|
L
 52.2%
H
13.2
22.1
|
L
 122.2%
H
8.9
22.1
|
L
 31.3%
H
6.5
22.1
|
L
 -16.9%
H
6.5
36.1
|
L
 -3.2%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr Reddys Laboratories ADR |
|
11,164.0
|
13.4
|
L
 0.9%
H
13.4
13.5
|
L
 -8.0%
H
13.1
14.7
|
L
 -4.7%
H
13.1
15.0
|
L
 -3.8%
H
13.1
15.1
|
L
 -9.7%
H
12.3
74.9
|
L
 21.1%
H
10.2
74.9
|
L
 1.7%
H
9.6
74.9
|
L
 1.5%
H
5.6
74.9
|
| Takeda Pharmaceutical Co ADR |
|
42,396.3
|
13.4
|
L
 -0.2%
H
13.4
13.4
|
L
 -4.2%
H
13.0
14.2
|
L
 -7.1%
H
13.0
14.7
|
L
 -5.2%
H
13.0
15.7
|
L
 -3.9%
H
12.8
15.7
|
L
 2.2%
H
12.6
17.2
|
L
 -14.7%
H
12.3
20.0
|
L
 -44.7%
H
12.3
30.6
|
| Teva Pharmaceutical Industries |
|
23,539.5
|
20.5
|
L
 0.2%
H
20.3
20.9
|
L
 8.3%
H
19
20.9
|
L
 2.3%
H
18.8
20.9
|
L
 33.4%
H
15.5
20.9
|
L
 11.2%
H
12.5
22.8
|
L
 134.2%
H
7.1
22.8
|
L
 133.2%
H
6.8
22.8
|
L
 -66.3%
H
6.1
66.6
|
| Usana Health Sciences Inc |
|
388.3
|
21.3
|
L
 0.5%
H
20.9
21.6
|
L
 2.2%
H
19.5
21.6
|
L
 -22.6%
H
18.7
28.0
|
L
 -26.4%
H
18.7
32.3
|
L
 -43.0%
H
18.7
41.8
|
L
 -58.5%
H
18.7
69.6
|
L
 -72.0%
H
18.7
107.9
|
L
 -67.4%
H
18.7
138.0
|
| Zoetis |
|
63,973.5
|
144.4
|
L
 0.2%
H
142.1
144.8
|
L
 -1.1%
H
142.1
147.9
|
L
 -1.5%
H
140.7
148.8
|
L
 -2.1%
H
139.3
160.5
|
L
 -20.7%
H
139.3
181.9
|
L
 -2.0%
H
124.2
201.9
|
L
 -11.4%
H
124.2
249.3
|
L
 226.3%
H
38.3
249.3
|
| Biohaven |
|
1,571.0
|
14.9
|
L
 -13.7%
H
14.4
16.5
|
L
 -10.5%
H
14.4
18.6
|
L
 -4.3%
H
14.4
18.6
|
L
 1.0%
H
12.8
18.6
|
L
 -70.4%
H
12.8
55.0
|
L
 1.1%
H
12.4
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
104.6
|
2.2
|
L
 -7.5%
H
2.2
2.4
|
L
 -7.9%
H
2.2
2.5
|
L
 14.4%
H
1.9
3.8
|
L
 27.6%
H
1.6
3.8
|
L
 11.6%
H
1.4
3.8
|
L
 -82.2%
H
1.2
14.1
|
L
 -88.2%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,604.7
|
5.4
|
L
 -3.2%
H
5.2
5.6
|
L
 -5.1%
H
5.2
5.8
|
L
 -10.2%
H
5.2
6.5
|
L
 26.7%
H
3.8
6.5
|
L
 93.2%
H
1.9
6.5
|
L
 -55.3%
H
1.9
15.0
|
L
H
1.9
71.9
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
245.1
|
4.8
|
L
 -0.6%
H
4.7
4.9
|
L
 -12.8%
H
4.7
5.6
|
L
 -10.2%
H
4.7
5.7
|
L
 -26.4%
H
4.7
7.5
|
L
 -23.5%
H
3.9
7.5
|
L
 7.2%
H
2.2
9.0
|
L
 -81.4%
H
2.2
94.8
|
L
 -95.4%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,267.2
|
26.2
|
L
 -7.0%
H
25.8
28.2
|
L
 -3.9%
H
25.8
29.5
|
L
 36.6%
H
19.0
29.5
|
L
 92.6%
H
12.8
29.5
|
L
 -3.7%
H
5.5
29.5
|
L
 2.7%
H
2.2
53.9
|
L
 -46.1%
H
2.2
66
|
L
 -97.7%
H
2.2
1505.5
|
| Acumen Pharmaceuticals Inc |
|
132.1
|
2.2
|
L
 -1.4%
H
2.1
2.2
|
L
 -1.4%
H
2.1
2.5
|
L
 23.2%
H
1.7
2.5
|
L
 61.5%
H
1.2
2.5
|
L
 -23.2%
H
0.9
3.4
|
L
 -68.4%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
878.0
|
4.6
|
L
 -3.2%
H
4.6
4.8
|
L
 5.1%
H
4.3
4.9
|
L
 2%
H
4.1
4.9
|
L
 40.1%
H
3.3
5.1
|
L
 15.7%
H
2.7
5.1
|
L
 95.7%
H
1.7
5.1
|
L
 65.9%
H
1.7
6.5
|
L
 -21.4%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
69.7
|
3.0
|
L
 5.7%
H
2.8
3.0
|
L
 -0.7%
H
2.8
3.0
|
L
 -2.0%
H
2.8
3.4
|
L
 7.6%
H
2.5
3.4
|
L
 348.5%
H
0.4
5.5
|
L
 -61.1%
H
0.4
18.7
|
L
 -92.6%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
| Acadia Pharmaceuticals Inc |
|
3,774.1
|
22.4
|
L
 -1.5%
H
21.9
22.8
|
L
 1.6%
H
21.9
23.0
|
L
 4.6%
H
19.7
23.0
|
L
 -4.9%
H
19.7
26.7
|
L
 51.1%
H
13.4
26.7
|
L
 40.4%
H
13.4
33.9
|
L
 -51.0%
H
12.2
57.5
|
L
 -44.3%
H
12.2
58.7
|
| Adicet Bio Inc |
|
111.9
|
0.7
|
L
 -2.7%
H
0.7
0.8
|
L
 -18.0%
H
0.7
0.9
|
L
 -12.1%
H
0.7
1.1
|
L
 9.0%
H
0.6
1.1
|
L
 -41.6%
H
0.5
1.4
|
L
 -95.8%
H
0.5
21.9
|
L
 -93.0%
H
0.5
21.9
|
L
H
0.5
147.7
|
| Achieve Life Sciences Inc |
|
261.1
|
5.1
|
L
 -0.2%
H
5.0
5.3
|
L
 2.2%
H
4.7
5.4
|
L
 60.2%
H
3.0
5.8
|
L
 100.4%
H
2.4
5.8
|
L
 8.5%
H
1.8
5.8
|
L
 136.6%
H
1.8
10.3
|
L
 -35.2%
H
1.8
16.1
|
L
 -99.9%
H
1.8
6160
|
| AC Immune SA |
|
319.9
|
3.2
|
L
 -5.9%
H
3.1
3.4
|
L
 -2.2%
H
3.1
4
|
L
 1.6%
H
2.6
4
|
L
 50%
H
2.0
4
|
L
 6%
H
1.4
4
|
L
 10.4%
H
1.4
5.1
|
L
 -30.6%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
4,776.7
|
86.1
|
L
 -4.6%
H
84.5
92.3
|
L
 1.7%
H
84.5
92.3
|
L
 4.7%
H
82.2
94.1
|
L
 21.1%
H
66.5
94.1
|
L
 -0.1%
H
47.9
107.4
|
L
 282.5%
H
18.7
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Aclaris Therapeutics Inc |
|
277.3
|
2.6
|
L
 1.6%
H
2.4
2.7
|
L
 19.1%
H
2.2
2.7
|
L
 39.1%
H
1.7
2.7
|
L
 67.3%
H
1.5
2.7
|
L
 22.5%
H
1.1
5.2
|
L
 -83.1%
H
0.6
19.0
|
L
 -31.7%
H
0.6
30.4
|
L
 -82.5%
H
0.6
33.9
|
| Acrivon Therapeutics Inc |
|
73.3
|
2.3
|
L
 17.1%
H
2.1
2.5
|
L
 12.6%
H
1.9
2.5
|
L
 25.3%
H
1.7
2.5
|
L
 84.9%
H
1.2
2.7
|
L
 -70.8%
H
1.1
8.7
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharmaceuticals Inc |
|
23.9
|
1.4
|
L
 5.2%
H
1.3
1.4
|
L
 22.6%
H
1.2
1.4
|
L
 50%
H
0.9
1.5
|
L
 252.5%
H
0.4
1.5
|
L
 182%
H
0.4
1.5
|
L
 -37.9%
H
0.4
3.0
|
L
 -96.1%
H
0.4
58.8
|
L
 -98.4%
H
0.4
117.6
|
| Grace Therapeutics Inc |
|
47.2
|
3.1
|
L
 -1.6%
H
3.1
3.2
|
L
 -1.0%
H
3.1
3.3
|
L
 3.0%
H
3.0
3.4
|
L
 8.4%
H
2.8
3.4
|
L
 0.3%
H
1.8
5.0
|
L
 -9.1%
H
1.7
5.1
|
L
 -65.5%
H
1.7
58.6
|
L
 -97.2%
H
1.7
161.1
|
| Acurx Pharmaceuticals Inc |
|
10.5
|
5.1
|
L
 0.8%
H
4.9
5.6
|
L
 -22.3%
H
4.9
6.8
|
L
 11.0%
H
4.1
8.3
|
L
 -17.6%
H
3.8
8.3
|
L
 -86.4%
H
3.8
38
|
L
 -90.8%
H
3.8
176.4
|
L
H
3.8
176.4
|
L
H
3.8
176.4
|
| Adial Pharmaceuticals Inc |
|
7.4
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 -5.6%
H
0.3
0.4
|
L
 -15%
H
0.3
0.4
|
L
 -26.1%
H
0.3
0.5
|
L
 -66.3%
H
0.2
1.3
|
L
 -95.3%
H
0.2
15
|
L
 -99.2%
H
0.2
127
|
L
H
0.2
236
|
| Adma Biologics Inc |
|
3,667.8
|
15.4
|
L
 -0.7%
H
15.1
15.7
|
L
 1.3%
H
14.6
15.8
|
L
 5.8%
H
13.8
16.1
|
L
 -20.5%
H
13.8
20.3
|
L
 -20.7%
H
13.5
25.7
|
L
 482.2%
H
2.5
25.7
|
L
 638.9%
H
1.0
25.7
|
L
 68.0%
H
1.0
25.7
|
| Adaptive Biotechnologies Corp |
|
2,640.4
|
17.3
|
L
 -0.1%
H
17
17.5
|
L
 0.7%
H
16.6
17.8
|
L
 21.8%
H
14.1
17.9
|
L
 67.9%
H
10.2
17.9
|
L
 226.6%
H
4.3
17.9
|
L
 120.9%
H
2.3
17.9
|
L
 -62.2%
H
2.3
71.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
32.4
|
6.5
|
L
 -3.0%
H
5.2
7.1
|
L
 -73.2%
H
5.2
27.0
|
L
 -92.4%
H
5.2
86.7
|
L
 -94.4%
H
5.2
145.2
|
L
 -100.0%
H
5.2
438581.3
|
L
 -100.0%
H
5.2
4321120000
|
L
 -100.0%
H
5.2
10000000000
|
L
H
5.2
10000000000
|
| Adverum Biotechnologies Inc |
|
94.4
|
4.3
|
L
 -0.2%
H
4.2
4.3
|
L
 5.4%
H
4.0
4.3
|
L
 -18.6%
H
4.0
5.6
|
L
 84.9%
H
2.2
5.8
|
L
 -42.1%
H
1.8
8.2
|
L
 -94.9%
H
1.8
297
|
L
 -99.6%
H
1.8
1479
|
L
 -99.5%
H
1.8
2698
|
| Agenus Inc |
|
126.5
|
4.0
|
L
H
3.9
4
|
L
 -4.1%
H
3.8
4.2
|
L
 0.8%
H
3.8
4.6
|
L
 -25.9%
H
3.8
5.6
|
L
 -2.0%
H
1.4
7.3
|
L
 -91.7%
H
1.4
196
|
L
 -94.6%
H
1.4
196
|
L
 -95.8%
H
1.4
196
|
| Agios Pharmaceuticals Inc |
|
2,340.1
|
40.1
|
L
 -7.2%
H
40.0
44.1
|
L
 -7.4%
H
40.0
44.3
|
L
 0.5%
H
39.7
44.3
|
L
 14.7%
H
26.8
44.3
|
L
 -10.6%
H
23.4
62.6
|
L
 44.2%
H
19.8
62.6
|
L
 0.0%
H
16.8
62.6
|
L
 -48.5%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
96.3
|
23.8
|
L
 -2.8%
H
22.4
24.5
|
L
 1.8%
H
22.4
25.1
|
L
 48.8%
H
15.9
25.1
|
L
 46.3%
H
14.5
25.1
|
L
 56.7%
H
13.9
25.1
|
L
 -22.0%
H
2.7
39
|
L
 -87.1%
H
2.7
247.5
|
L
H
2.7
318.8
|
| Akebia Therapeutics Inc |
|
562.1
|
2.1
|
L
 -4.1%
H
2.1
2.2
|
L
 -30.0%
H
2.1
3.2
|
L
 -21.8%
H
2.1
3.2
|
L
 -43.0%
H
2.1
3.8
|
L
 25.4%
H
1.5
4.1
|
L
 685.2%
H
0.2
4.1
|
L
 -8.2%
H
0.2
5.1
|
L
 -78.7%
H
0.2
20.3
|
| Akero Therapeutics Inc |
|
4,336.1
|
54.1
|
L
 -0.2%
H
54
54.2
|
L
 0.6%
H
53.7
54.3
|
L
 16.6%
H
45.2
54.5
|
L
 11.8%
H
41.8
54.5
|
L
 67.3%
H
21.3
58.4
|
L
 29.1%
H
11.3
58.4
|
L
 100.4%
H
7.5
58.4
|
L
H
7.5
58.4
|
| Avalon GloboCare Corp |
|
8.0
|
2.1
|
L
 -1.4%
H
2.0
2.1
|
L
 -5.9%
H
2.0
2.2
|
L
 -7.1%
H
2.0
2.5
|
L
 -3.2%
H
1.9
2.9
|
L
 -30.3%
H
1.9
11.7
|
L
 -45.3%
H
0.2
11.7
|
L
 -82.0%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
314.0
|
5.2
|
L
 3.2%
H
5.0
5.2
|
L
 -0.2%
H
4.7
5.4
|
L
 -1.7%
H
4.7
5.8
|
L
 8.7%
H
4.7
6.2
|
L
 -2.4%
H
1.1
7.2
|
L
 -3.3%
H
1.1
12.0
|
L
 -19.9%
H
1.1
16.0
|
L
 -27.6%
H
1.1
16.7
|
| Alector Inc |
|
145.7
|
1.4
|
L
 -2.0%
H
1.4
1.5
|
L
 -4%
H
1.4
1.7
|
L
 -54.4%
H
1.3
3.4
|
L
 -0.7%
H
1.3
3.4
|
L
 -71.3%
H
0.9
6.1
|
L
 -84.0%
H
0.9
9.9
|
L
 -85.1%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
52.3
|
7.5
|
L
 -8.7%
H
7.5
8.5
|
L
 -22.2%
H
7.5
10.1
|
L
 -26.5%
H
7.5
11.2
|
L
 0.9%
H
7.1
11.7
|
L
 -21.2%
H
3.8
46.3
|
L
 -71.9%
H
3.8
60.3
|
L
 -98.0%
H
3.8
937.8
|
L
H
3.8
937.8
|
| Alkermes plc |
|
4,981.6
|
30.2
|
L
 -1.7%
H
29.7
30.7
|
L
 1.2%
H
28.4
32.1
|
L
 -3.5%
H
28.4
32.4
|
L
 13.6%
H
25.2
32.4
|
L
 14.0%
H
25.2
36.5
|
L
 25.4%
H
22.0
36.5
|
L
 84.2%
H
15.9
36.5
|
L
 -59.2%
H
12.0
80.7
|
| Allogene Therapeutics Inc |
|
261.8
|
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 -1.7%
H
1.2
1.3
|
L
 -8.5%
H
1.2
1.5
|
L
 9.3%
H
1.0
1.5
|
L
 -56.6%
H
0.9
3.8
|
L
 -88.4%
H
0.9
11.1
|
L
 -96.5%
H
0.9
39.1
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
20.0
|
1.4
|
L
 -4.8%
H
1.3
1.4
|
L
 -0.7%
H
1.3
1.5
|
L
 -14.8%
H
1.3
1.8
|
L
 36.6%
H
0.8
2.1
|
L
H
0.6
2.1
|
L
 -100.0%
H
0.1
37800
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharmaceuticals Inc |
|
57,346.6
|
434.1
|
L
 -4.8%
H
429.6
457.3
|
L
 -6.3%
H
429.6
485.4
|
L
 -5.8%
H
429.6
495.6
|
L
 8.0%
H
398.9
495.6
|
L
 58.5%
H
205.9
495.6
|
L
 102.5%
H
142.0
495.6
|
L
 247.5%
H
117.6
495.6
|
L
 366.4%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
42.0
|
1.8
|
L
 12.2%
H
1.6
2.2
|
L
 21.5%
H
1.3
2.2
|
L
 50.9%
H
1.2
2.2
|
L
 57.7%
H
1.0
2.2
|
L
 -56.3%
H
1.0
4.2
|
L
 -55.8%
H
1.0
7.4
|
L
 -92.3%
H
1.0
46.6
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
349.5
|
4.0
|
L
 -2.2%
H
3.9
4.1
|
L
 0.3%
H
3.9
4.3
|
L
 0.8%
H
3.8
4.3
|
L
 9.7%
H
3.3
4.3
|
L
 -41.3%
H
2.9
11.2
|
L
 -66.6%
H
2.1
17.2
|
L
 -65.1%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
| Alvotech |
|
1,567.4
|
5.0
|
L
 -34.3%
H
4.8
5.9
|
L
 -40.1%
H
4.8
8.5
|
L
 -38.7%
H
4.8
9.0
|
L
 -42.8%
H
4.8
9.3
|
L
 -61.5%
H
4.8
13.7
|
L
 -19.5%
H
4.8
18
|
L
H
4.8
18
|
L
H
4.8
18
|
| Kalaris Therapeutics Inc |
|
93.3
|
5.0
|
L
 -0.8%
H
4.8
5.5
|
L
 4.6%
H
4.6
5.5
|
L
 -29.6%
H
4.3
8.8
|
L
 85.5%
H
2.1
8.8
|
L
 425.3%
H
0.4
12.9
|
L
 -29.0%
H
0.4
12.9
|
L
 -81.0%
H
0.4
49.0
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
9.7
|
2.5
|
L
 0.4%
H
2.4
2.6
|
L
 2.0%
H
2.3
2.7
|
L
 2.8%
H
2.1
2.7
|
L
 15.5%
H
2.1
2.7
|
L
 -82.8%
H
2.1
15.2
|
L
 -99.8%
H
2.1
1782
|
L
H
2.1
45292.5
|
L
H
2.1
45292.5
|
| Amgen |
|
159,516.6
|
296.3
|
L
 -0.7%
H
292.1
301
|
L
 1.6%
H
288
301
|
L
 -0.4%
H
288
303.9
|
L
 -0.2%
H
269.8
303.9
|
L
 -7.2%
H
253.3
335.9
|
L
 10.1%
H
211.7
346.9
|
L
 34.6%
H
198.6
346.9
|
L
 82.6%
H
133.6
346.9
|
| Amylyx Pharmaceuticals Inc |
|
1,450.7
|
13.6
|
L
 -2.4%
H
13.3
14.0
|
L
 -4.0%
H
13.3
14.6
|
L
 2.3%
H
12.3
17.0
|
L
 76.2%
H
7.5
17.0
|
L
 141.1%
H
2.6
17.0
|
L
 -61.1%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharmaceuticals Inc |
|
1,176.3
|
25.3
|
L
 -0.8%
H
24.9
25.9
|
L
 3.2%
H
23.8
25.9
|
L
 -4.6%
H
22.9
27.3
|
L
 19.3%
H
20.7
31.3
|
L
 -50.1%
H
20.4
54.0
|
L
 -16.6%
H
20.4
67.7
|
L
 27.1%
H
16.9
67.7
|
L
 101.9%
H
10.5
67.7
|
| AnaptysBio Inc |
|
1,008.1
|
36.0
|
L
 -1.5%
H
35.5
37.1
|
L
 2.8%
H
35.1
38.4
|
L
 15%
H
29.5
38.4
|
L
 46.0%
H
17.1
38.4
|
L
 66.2%
H
12.2
38.4
|
L
 23.3%
H
12.2
41.3
|
L
 20.1%
H
12.2
41.3
|
L
H
10
134
|
| Anebulo Pharmaceuticals Inc |
|
104.4
|
2.5
|
L
 -3.8%
H
2.5
2.7
|
L
 -7.6%
H
2.5
2.8
|
L
 5.8%
H
2.2
2.9
|
L
 -10.9%
H
1.8
2.9
|
L
 38.0%
H
0.8
3.4
|
L
 -7.3%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| ANI Pharmaceuticals Inc |
|
2,096.8
|
94.1
|
L
 3.8%
H
89.0
94.2
|
L
 -0.2%
H
89.0
96.6
|
L
 5.5%
H
87.6
97
|
L
 47.1%
H
63.7
99.5
|
L
 61.6%
H
52.5
99.5
|
L
 146.6%
H
32.2
99.5
|
L
 242.0%
H
22.3
99.5
|
L
 110.1%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
136.3
|
4.1
|
L
 0.2%
H
3.8
4.2
|
L
H
3.8
4.5
|
L
 25.8%
H
3.2
5.0
|
L
 37.5%
H
2.9
5.0
|
L
 13.1%
H
2.1
5.0
|
L
 -22.0%
H
2.1
6.5
|
L
 91.7%
H
1.9
8.1
|
L
 20%
H
0.6
8.1
|
| Annexon Inc |
|
348.3
|
3.2
|
L
 0.3%
H
3.1
3.4
|
L
 -1.3%
H
2.9
3.6
|
L
 1.9%
H
2.9
3.6
|
L
 29.4%
H
2.0
3.6
|
L
 -56.2%
H
1.3
7.6
|
L
 -31.5%
H
1.3
8.4
|
L
 -86.2%
H
1.3
38.0
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
31.4
|
1.2
|
L
 -6.5%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.4
|
L
 -10.2%
H
1.1
1.4
|
L
 8.5%
H
1.0
1.4
|
L
 6.5%
H
1.0
1.7
|
L
 -92.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
4.4
|
3.4
|
L
 -1.5%
H
3.3
3.6
|
L
 -10.1%
H
3.3
3.9
|
L
 -17.1%
H
3.3
6.2
|
L
 -25.6%
H
2.1
7.2
|
L
 -97.7%
H
0.7
190.8
|
L
 -100.0%
H
0.7
28950
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2928000
|
| Apollomics Inc Ordinary |
|
30.4
|
14.2
|
L
 1.4%
H
12.9
15.8
|
L
 -38.4%
H
10.0
27.7
|
L
 -23.1%
H
10.0
42.1
|
L
 141.4%
H
3.7
42.1
|
L
 19.1%
H
0.1
42.1
|
L
 -98.6%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharmaceuticals Inc |
|
2,617.8
|
20.7
|
L
 -3.6%
H
20.1
21.4
|
L
 -26.6%
H
19.3
30.5
|
L
 -10.5%
H
19.3
30.5
|
L
 -9.9%
H
19.3
30.5
|
L
 -26.1%
H
16.1
35.7
|
L
 -65.1%
H
16.1
94.8
|
L
 -34.4%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
149.8
|
1.0
|
L
 -9.6%
H
1.0
1.2
|
L
 -24.1%
H
1.0
1.4
|
L
 11.8%
H
0.9
1.5
|
L
 136.4%
H
0.4
1.5
|
L
 -88.6%
H
0.3
10.6
|
L
 25.3%
H
0.3
10.6
|
L
 -94.1%
H
0.3
29.8
|
L
H
0.3
57.4
|
| Aptorum Group Ordinary |
|
11.6
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -4.7%
H
1.4
1.5
|
L
 -35.8%
H
1.4
2.6
|
L
 3.7%
H
1.2
4.5
|
L
 -2.1%
H
0.5
7.5
|
L
 -77.5%
H
0.5
17.5
|
L
 -93.2%
H
0.5
49.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
8.2
|
1.4
|
L
H
1.4
1.5
|
L
H
1.3
1.5
|
L
 -5.4%
H
1.3
1.7
|
L
 -15.7%
H
1.3
1.8
|
L
 -64.3%
H
1.3
5
|
L
 -89.7%
H
1.3
14.0
|
L
 -99.7%
H
1.3
619.8
|
L
H
1.3
1062.2
|
| Aptevo Therapeutics Inc |
|
20.3
|
1.5
|
L
 -5.2%
H
1.5
1.5
|
L
 -3.3%
H
1.4
1.6
|
L
 1.4%
H
1.4
2.0
|
L
 -45.2%
H
1.3
2.8
|
L
 -99.2%
H
1.3
298
|
L
 -100.0%
H
1.3
234432
|
L
 -100.0%
H
1.3
1953600
|
L
H
1.3
3778913.6
|
| AquaBounty Technologies Inc |
|
4.7
|
1.2
|
L
 -6.2%
H
1.2
1.3
|
L
 -17.6%
H
1.2
1.5
|
L
 -57.2%
H
1.2
2.8
|
L
 69.4%
H
0.7
3.0
|
L
 3.4%
H
0.5
3.0
|
L
 -91.1%
H
0.5
23.6
|
L
 -98.3%
H
0.5
266.4
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
785.1
|
6.5
|
L
 -4.8%
H
6.2
6.8
|
L
 -5.1%
H
6.2
7.1
|
L
 12.5%
H
5.7
7.6
|
L
 69.9%
H
3.7
7.6
|
L
 17.6%
H
2.1
7.6
|
L
 672.6%
H
0.7
7.6
|
L
 35.2%
H
0.6
8.1
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings |
|
252.5
|
9.3
|
L
 -6.7%
H
9.2
10.1
|
L
 -17.1%
H
9.2
11.5
|
L
 -57.5%
H
9.2
24.2
|
L
 -24.4%
H
9.2
24.2
|
L
 -48.3%
H
8.0
24.2
|
L
 -57.1%
H
8.0
45
|
L
 -83.2%
H
8.0
129.7
|
L
 -84.0%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,438.4
|
5.9
|
L
 -2.3%
H
5.8
6.4
|
L
 17.5%
H
4.9
6.7
|
L
 12.8%
H
4.7
6.7
|
L
 36.7%
H
4.2
6.8
|
L
 -2.8%
H
3.2
6.8
|
L
 302.7%
H
1.2
10.1
|
L
 14.1%
H
0.5
10.1
|
L
 -65.8%
H
0.5
21.0
|
| Arcutis Biotherapeutics Inc |
|
3,032.9
|
24.8
|
L
 -2.2%
H
24.2
25.4
|
L
 23.1%
H
19.6
27.1
|
L
 16.5%
H
19.4
27.1
|
L
 73.3%
H
13.7
27.1
|
L
 185.6%
H
8.3
27.1
|
L
 40.8%
H
1.8
27.1
|
L
 32.3%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
6.0
|
3
|
L
 -3.2%
H
3
3.2
|
L
 -11.2%
H
3
3.7
|
L
 -37.8%
H
3
5.0
|
L
 -70.6%
H
3
10.6
|
L
 -56.5%
H
3
28.6
|
L
 -82.5%
H
3
28.6
|
L
 -93.1%
H
3
330.3
|
L
H
3
15552
|
| Arvinas Inc |
|
713.6
|
9.7
|
L
 -4.1%
H
9.5
10.1
|
L
 5.5%
H
9.3
10.2
|
L
 4.9%
H
8.8
10.3
|
L
 31%
H
6.1
10.3
|
L
 -63.9%
H
5.9
28.8
|
L
 -80.1%
H
5.9
58.0
|
L
 -55.6%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharmaceuticals Inc |
|
5,476.4
|
39.6
|
L
 -6.6%
H
39.3
43.2
|
L
 4.2%
H
38.6
43.7
|
L
 14.5%
H
34.6
43.7
|
L
 148.7%
H
15.0
43.7
|
L
 103.2%
H
9.6
43.7
|
L
 14.4%
H
9.6
43.7
|
L
 -32.0%
H
9.6
93.7
|
L
 640.4%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
485.0
|
31.2
|
L
 0.4%
H
30
31.6
|
L
 6.6%
H
28.8
32.4
|
L
 31.5%
H
23.2
32.4
|
L
 69.4%
H
18.0
32.4
|
L
 84.6%
H
7.8
32.4
|
L
 60.3%
H
7.7
32.4
|
L
 -82.4%
H
7.7
196.8
|
L
 -72.0%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
1,011.8
|
9.2
|
L
 -9.7%
H
9.0
10.1
|
L
 -6.8%
H
9.0
11.2
|
L
 1.8%
H
8.5
14.5
|
L
 2.5%
H
7.7
14.5
|
L
 6.5%
H
3.7
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
71.2
|
0.7
|
L
H
0.7
0.8
|
L
 -9.8%
H
0.7
0.8
|
L
 -18.7%
H
0.7
0.9
|
L
 4.2%
H
0.7
1.0
|
L
 -28.2%
H
0.5
1.1
|
L
 -72.1%
H
0.5
8.0
|
L
 -70.8%
H
0.5
8.0
|
L
 -99.0%
H
0.5
108.1
|
| ATAI Life Sciences NV |
|
1,429.8
|
5.4
|
L
 -8.4%
H
5.3
5.9
|
L
 -7.3%
H
5.3
6.2
|
L
 4.1%
H
5.0
6.8
|
L
 28.3%
H
3.6
6.8
|
L
 395.4%
H
1.1
6.8
|
L
 70.4%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| Athira Pharma Inc |
|
16.5
|
4.2
|
L
 0.5%
H
4.0
4.2
|
L
 2.7%
H
3.8
4.2
|
L
 0.5%
H
3.6
4.6
|
L
 13.0%
H
3.5
4.6
|
L
 -29.4%
H
2.2
8.3
|
L
 -86.3%
H
2.2
44.1
|
L
 -97.7%
H
2.2
347.9
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
286.7
|
17.3
|
L
 -11.9%
H
17.2
19.5
|
L
 -4.1%
H
17.2
24.4
|
L
 -33.0%
H
14.5
27.1
|
L
 -51.1%
H
14.5
174.6
|
L
 -53.7%
H
6.6
174.6
|
L
 -98.9%
H
6.6
2124.2
|
L
 -99.9%
H
6.6
49571
|
L
H
6.6
49571
|
| Atossa Therapeutics Inc |
|
111.1
|
0.9
|
L
 -3.4%
H
0.9
0.9
|
L
 -7.5%
H
0.9
1.0
|
L
 -6.5%
H
0.9
1.3
|
L
 4.9%
H
0.7
1.3
|
L
 -39.4%
H
0.6
1.7
|
L
 -6.5%
H
0.5
2.3
|
L
 -42.7%
H
0.5
9.8
|
L
 -99.3%
H
0.5
135
|
| Atara Biotherapeutics Inc |
|
97.3
|
13.9
|
L
 -6.7%
H
13.7
15.3
|
L
 -4.4%
H
13.3
15.7
|
L
 -4.4%
H
13.3
16.7
|
L
 19.9%
H
10.3
16.7
|
L
 42.6%
H
5
18.7
|
L
 -88.1%
H
0.4
141
|
L
 -95.6%
H
0.4
705
|
L
 -98.1%
H
0.4
1361.3
|
| Astria Therapeutics Inc |
|
699.2
|
12.4
|
L
 -1.9%
H
12.3
12.6
|
L
 -0.4%
H
12.3
12.7
|
L
 61.1%
H
7.3
12.7
|
L
 88.9%
H
6.1
12.7
|
L
 9.5%
H
3.6
12.7
|
L
 19.8%
H
3.6
16.9
|
L
 51.8%
H
2.4
47.8
|
L
 -97.2%
H
2.4
649.8
|
| Aurinia Pharmaceuticals Inc |
|
1,733.6
|
13.2
|
L
H
12.8
13.5
|
L
 10.8%
H
11.9
13.5
|
L
 17.0%
H
10.9
13.5
|
L
 25.6%
H
10.3
13.5
|
L
 79.9%
H
6.6
13.5
|
L
 73.1%
H
4.1
13.5
|
L
 -15.0%
H
4.1
34.0
|
L
 336.1%
H
1.4
34.0
|
| Aura Biosciences Inc |
|
375.2
|
6.0
|
L
 -1.5%
H
5.9
6.2
|
L
 3.1%
H
5.9
6.6
|
L
 0.3%
H
5.6
6.6
|
L
 -10.4%
H
5.6
7.4
|
L
 -41.6%
H
4.3
11.3
|
L
 -51.0%
H
4.3
14.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharmaceuticals Inc |
|
257.9
|
3.3
|
L
H
3.2
3.3
|
L
 1.3%
H
3.2
3.3
|
L
 15.3%
H
2.8
3.3
|
L
 -6.3%
H
2.8
3.9
|
L
 -1.5%
H
2.5
4.0
|
L
 -44.9%
H
2.5
6.2
|
L
 -89.1%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
327.6
|
17.5
|
L
 -4.1%
H
16.6
18.5
|
L
 2.1%
H
16.6
26
|
L
 14.8%
H
14.6
26
|
L
 -15.5%
H
14.4
27.3
|
L
 -57.2%
H
13.7
61.1
|
L
 115.9%
H
1.4
61.1
|
L
 -89.5%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
435.6
|
9.5
|
L
 -3.4%
H
9.3
10.0
|
L
 -5.3%
H
9.3
10.5
|
L
 13.7%
H
8.2
10.5
|
L
 37.5%
H
6.7
10.5
|
L
 -90.3%
H
6.6
100.3
|
L
 -98.6%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
296.7
|
16.7
|
L
 -7.5%
H
16.3
18.7
|
L
 -5.1%
H
16.3
19.0
|
L
 28.2%
H
12.8
19.4
|
L
 111.3%
H
7.9
19.4
|
L
 28.6%
H
3.4
19.4
|
L
 141.6%
H
0.0
34.5
|
L
 -31.2%
H
0.0
54
|
L
H
0.0
91.8
|
| Anavex Life Sciences |
|
664.8
|
7.7
|
L
 -2.9%
H
7.5
7.9
|
L
 -10.2%
H
7.5
8.8
|
L
 -15.2%
H
7.5
10.4
|
L
 -30.9%
H
7.5
11.7
|
L
 13.2%
H
6.6
14.4
|
L
 -34.3%
H
3.3
15.2
|
L
 35.6%
H
3.3
31.5
|
L
 -40.5%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
6,774.1
|
135.8
|
L
 0.6%
H
123.5
137.9
|
L
 4.8%
H
123.5
137.9
|
L
 13.2%
H
117.3
137.9
|
L
 31.8%
H
96.1
137.9
|
L
 52.8%
H
75.6
139.1
|
L
 168.8%
H
49.6
139.1
|
L
 103.0%
H
19.4
139.1
|
L
H
1.9
139.1
|
| Aytu BioPharma Inc |
|
22.5
|
2.2
|
L
 -2.6%
H
2.1
2.3
|
L
 -2.6%
H
2.1
2.3
|
L
 12.2%
H
1.9
2.6
|
L
 -7.9%
H
1.7
2.8
|
L
 13.9%
H
1.0
2.8
|
L
 -34.2%
H
1.0
4.9
|
L
 -98.8%
H
1.0
235.3
|
L
 -100.0%
H
1.0
4272000
|
| Aziyo Biologics Inc Ordinary |
|
-
|
0.9
|
L
 3.3%
H
0.9
1.0
|
L
 4.4%
H
0.9
1.0
|
L
 4.4%
H
0.9
1
|
L
 -53.9%
H
0.9
2.4
|
L
 -45.4%
H
0.9
2.6
|
L
 -88.6%
H
0.9
9.0
|
L
 -91.8%
H
0.9
18.2
|
L
H
0.9
18.2
|
| Adagene Inc ADR |
|
84.4
|
1.8
|
L
 0.6%
H
1.7
1.8
|
L
H
1.7
1.9
|
L
 -7.7%
H
1.7
2.1
|
L
 -6.8%
H
1.7
3.2
|
L
 -40.3%
H
1.3
3.2
|
L
 94.6%
H
0.9
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics ADR |
|
8.1
|
8.7
|
L
 -4.4%
H
8.6
8.9
|
L
 -9.3%
H
8.6
9.9
|
L
 -7.2%
H
8.5
12.0
|
L
 7.5%
H
7.5
12.1
|
L
 -18.6%
H
6.5
12.1
|
L
 -47.5%
H
5
45.6
|
L
 -96.1%
H
5
700
|
L
H
5
750.4
|
| Akari Therapeutics Plc ADR |
|
23.5
|
0.7
|
L
 -4%
H
0.7
0.8
|
L
 -2.7%
H
0.7
0.8
|
L
 -22.6%
H
0.7
1.1
|
L
 -28.7%
H
0.6
1.2
|
L
 -74.1%
H
0.6
2.9
|
L
 -92.7%
H
0.6
12.6
|
L
 -97.6%
H
0.6
84.2
|
L
 -99.8%
H
0.6
444
|
| Amarin Corp ADR |
|
325.6
|
15.7
|
L
 -3.9%
H
15.5
16.5
|
L
 -20.6%
H
15.5
20.6
|
L
 -6.5%
H
15.5
20.9
|
L
 3.3%
H
14.5
20.9
|
L
 2554.2%
H
0.4
20.9
|
L
 1142.9%
H
0.4
20.9
|
L
 217.0%
H
0.4
20.9
|
L
 679.1%
H
0.4
26.1
|
| Argen X SE ADR |
|
50,873.2
|
826.3
|
L
 1.0%
H
809.1
832.4
|
L
 1.1%
H
749.8
842.2
|
L
 4.4%
H
749.8
855.5
|
L
 22.6%
H
631.5
855.5
|
L
 38.7%
H
510.1
855.5
|
L
 122.3%
H
327.7
855.5
|
L
 231.2%
H
246.0
855.5
|
L
H
17.3
855.5
|
| Ascendis Pharma AS ADR |
|
12,170.2
|
201.0
|
L
 -0.3%
H
195.0
203.8
|
L
 -0.5%
H
195.0
208.9
|
L
H
186.1
216.5
|
L
 15.2%
H
173.3
216.5
|
L
 60.4%
H
118.0
216.5
|
L
 76.4%
H
64.3
216.5
|
L
 23.7%
H
61.6
216.5
|
L
 1001.9%
H
11.9
216.5
|
| Alterity Therapeutics ADR |
|
73.0
|
4.0
|
L
 -4.3%
H
4.0
4.1
|
L
 -11.2%
H
4.0
4.9
|
L
 -3.8%
H
4.0
5.2
|
L
 -19.6%
H
3.8
5.6
|
L
 250.4%
H
1
7
|
L
 15.1%
H
1
7
|
L
 -65.8%
H
1
35.8
|
L
 -92.0%
H
1
66.9
|
| Autolus Therapeutics plc ADR |
|
415.2
|
1.6
|
L
 0.7%
H
1.5
1.6
|
L
 2.0%
H
1.5
1.7
|
L
 -3.1%
H
1.5
1.8
|
L
 -33.6%
H
1.3
2.5
|
L
 -55.4%
H
1.1
4.1
|
L
 -43.9%
H
1.1
7.5
|
L
 -86.2%
H
1.1
12.3
|
L
H
1.1
53.2
|
| Avadel Pharmaceuticals plc |
|
1,842.9
|
18.9
|
L
 0.2%
H
18.7
19
|
L
 1.9%
H
18.5
19.1
|
L
 26.6%
H
13.8
19.1
|
L
 70.8%
H
10.8
19.1
|
L
 25.7%
H
6.4
19.1
|
L
 180.3%
H
5.6
19.1
|
L
 251.7%
H
1.1
19.1
|
L
 11.5%
H
1.0
19.1
|
| Astrazeneca plc ADR |
|
253,374.4
|
81.7
|
L
 -0.8%
H
81.1
82.4
|
L
 -1.9%
H
81.1
84.2
|
L
 -2.3%
H
81.1
86.6
|
L
 10.5%
H
72.9
86.6
|
L
 14.4%
H
61.2
86.6
|
L
 36.9%
H
58.9
87.7
|
L
 61.4%
H
46.5
87.7
|
L
 153.1%
H
25.6
87.7
|
| BridgeBio Pharma Inc |
|
11,944.1
|
62.0
|
L
 -1.1%
H
60.8
64.2
|
L
 14.2%
H
56.7
69.5
|
L
 16.3%
H
52
69.5
|
L
 30.8%
H
42.1
69.5
|
L
 143.3%
H
21.7
69.5
|
L
 522.9%
H
6.6
69.5
|
L
 60.7%
H
5.0
73.5
|
L
H
5.0
73.5
|
| BioAtla Inc |
|
38.8
|
0.7
|
L
 -5.7%
H
0.7
0.7
|
L
 -13.2%
H
0.7
0.8
|
L
H
0.6
1.1
|
L
 100%
H
0.3
1.1
|
L
 -67%
H
0.2
2.5
|
L
 -89.8%
H
0.2
11.7
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
14.8
|
1.4
|
L
 -0.7%
H
1.4
1.5
|
L
H
1.3
1.5
|
L
 3.0%
H
1.3
1.6
|
L
 -34.7%
H
1
2.3
|
L
 -41.8%
H
1
3.2
|
L
 -95.3%
H
1
43.8
|
L
 -95.2%
H
1
129
|
L
 -98.9%
H
1
2073.6
|
| Biocryst Pharmaceuticals Inc |
|
1,444.2
|
6.9
|
L
 -6.3%
H
6.8
7.3
|
L
 -4.7%
H
6.8
7.5
|
L
 -6.4%
H
6
7.5
|
L
 -13.7%
H
6
9.1
|
L
 -18.6%
H
6
11.3
|
L
 -42.9%
H
4.0
14.2
|
L
 78.6%
H
3.7
20.0
|
L
 -30.4%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
18.8
|
10
|
L
 -9.1%
H
9.8
11.0
|
L
 -27.5%
H
9.8
13.9
|
L
 -22.1%
H
9.8
14.7
|
L
 -86.6%
H
7.3
79
|
L
 -99.2%
H
7.3
1905
|
L
 -99.9%
H
7.3
12033
|
L
 -99.8%
H
7.3
18526.5
|
L
 -100.0%
H
7.3
138373.2
|
| Black Diamond Therapeutics Inc |
|
224.9
|
4.0
|
L
 2.1%
H
3.8
4.0
|
L
 0.5%
H
3.7
4.1
|
L
 5.9%
H
3.7
4.5
|
L
 52.5%
H
2.2
4.5
|
L
 36.7%
H
1.2
4.5
|
L
 73.2%
H
1.2
7.7
|
L
 -87.5%
H
1.2
37.8
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,453.2
|
24.3
|
L
 -3.0%
H
23.0
25.2
|
L
 -13.3%
H
23.0
27.6
|
L
 -5.2%
H
23.0
31.5
|
L
 28.8%
H
15.6
31.5
|
L
 7.4%
H
13.5
35.3
|
L
 -44.4%
H
13.5
54.3
|
L
 -30.0%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
11.7
|
1.1
|
L
H
1.1
1.1
|
L
H
1
1.2
|
L
 5.8%
H
0.9
1.2
|
L
 5.8%
H
0.8
1.2
|
L
 -0.9%
H
0.5
1.9
|
L
 -94.8%
H
0.5
22.4
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
22,216.6
|
151.4
|
L
 -1.8%
H
149.6
155.3
|
L
 1.0%
H
138
155.3
|
L
 -2.5%
H
138
160.2
|
L
 14.8%
H
127
160.2
|
L
 -12.9%
H
110.0
179.2
|
L
 -45.6%
H
110.0
319.8
|
L
 -39.2%
H
110.0
468.6
|
L
 -45.8%
H
110.0
468.6
|
| BioVie Inc |
|
12.9
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 -9.0%
H
1.7
2.0
|
L
 -14.5%
H
1.7
2.1
|
L
 -71.6%
H
1.4
6.2
|
L
 -93.8%
H
1.4
38.5
|
L
 -99.6%
H
1.4
1438
|
L
 -99.8%
H
1.4
4609.8
|
L
 -99.9%
H
1.4
5625
|
| Biomea Fusion Inc |
|
93.3
|
1.3
|
L
 -2.9%
H
1.3
1.4
|
L
 -9.6%
H
1.3
1.5
|
L
 -38.0%
H
1.3
3.0
|
L
 -15.9%
H
1.3
3.0
|
L
 -85.4%
H
1.3
9.3
|
L
 -88.3%
H
1.3
43.7
|
L
H
1.3
43.7
|
L
H
1.3
43.7
|
| Biomarin Pharmaceutical Inc |
|
10,153.2
|
52.9
|
L
 -1.3%
H
52.1
54.3
|
L
 -3.0%
H
51
56.8
|
L
 -4.9%
H
51
56.8
|
L
 -9.1%
H
51
64.0
|
L
 -20.7%
H
51
73.5
|
L
 -37.2%
H
51
117.8
|
L
 -28.0%
H
51
117.8
|
L
 -54.8%
H
51
131.9
|
| Bionano Genomics Inc |
|
16.7
|
1.7
|
L
 -4.4%
H
1.7
1.8
|
L
 -10.9%
H
1.7
2.0
|
L
 -9.0%
H
1.7
2.2
|
L
 -41.7%
H
1.5
5.5
|
L
 514.3%
H
0.1
11.6
|
L
 -92.3%
H
0.1
30.1
|
L
 -65.6%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
416.3
|
15.9
|
L
 -3.1%
H
13.1
16.3
|
L
 -4%
H
13.1
16.8
|
L
 15.6%
H
13.1
16.8
|
L
 44.7%
H
11.1
16.8
|
L
 45.2%
H
9.1
17.2
|
L
 405.1%
H
1.9
17.2
|
L
 -64.3%
H
1.9
178.3
|
L
 -98.9%
H
1.9
1521.4
|
| Bolt Biotherapeutics Inc |
|
10.7
|
5.6
|
L
 -3.1%
H
5.5
5.9
|
L
 -7%
H
5.5
6.4
|
L
 12.5%
H
5.0
6.6
|
L
 0.9%
H
4.6
6.6
|
L
 -57.7%
H
4.6
13.8
|
L
 -80.4%
H
4.6
40.6
|
L
H
4.6
861.4
|
L
H
4.6
861.4
|
| Bon Natural Life |
|
14.3
|
1.8
|
L
 -5.9%
H
1.8
1.9
|
L
 -8.3%
H
1.8
2.1
|
L
 -10.7%
H
1.8
2.3
|
L
 35.4%
H
1.3
3.4
|
L
 -94.8%
H
1.1
73.8
|
L
 -99.5%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
37.3
|
1.9
|
L
 -7.3%
H
1.9
2
|
L
 -18.5%
H
1.9
2.4
|
L
 -28.0%
H
1.9
2.9
|
L
 38.7%
H
1.6
8.1
|
L
 196.9%
H
0.2
8.1
|
L
 -84.2%
H
0.2
34.1
|
L
 -95.9%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
56.3
|
3.2
|
L
 -6.8%
H
2.9
3.3
|
L
 -10.5%
H
2.9
4
|
L
 0.3%
H
2.9
4.2
|
L
 -8.4%
H
2.5
4.2
|
L
 3850%
H
0.1
5.9
|
L
 156.9%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
83.5
|
2.1
|
L
 4.0%
H
2.0
2.3
|
L
 3.0%
H
1.8
2.3
|
L
 19.7%
H
1.6
2.4
|
L
H
1.6
2.4
|
L
 -7.2%
H
1.0
3.4
|
L
 176%
H
0.5
4
|
L
 -85.3%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics Plc ADR |
|
503.2
|
7.3
|
L
 -10.0%
H
7.3
8.1
|
L
 -7.9%
H
7.3
9.1
|
L
 -14.9%
H
7.3
9.2
|
L
 -9.1%
H
6.8
9.2
|
L
 -69.6%
H
6.1
25.4
|
L
 -70.4%
H
6.1
33.5
|
L
 -60.3%
H
6.1
62.1
|
L
H
6.1
62.1
|
| Biodexa Pharmaceuticals Plc |
|
3.8
|
6.2
|
L
 -2.4%
H
5
6.2
|
L
 -14.1%
H
5
7.8
|
L
 -7.4%
H
5
11.9
|
L
 -7.8%
H
5
11.9
|
L
 -89.5%
H
5
92
|
L
 -100.0%
H
5
4020000
|
L
 -100.0%
H
5
38295000
|
L
H
5
4045000000
|
| BeiGene ADR |
|
33,221.3
|
311.9
|
L
 0.4%
H
307
314.1
|
L
 0.3%
H
307
320.3
|
L
 -9.7%
H
306
353
|
L
 4.3%
H
280.1
355.3
|
L
 52.7%
H
171.0
355.3
|
L
 74.8%
H
127.0
355.3
|
L
 4.3%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx ADR |
|
14.8
|
3.5
|
L
H
3.4
3.6
|
L
 -6.7%
H
3.3
3.9
|
L
 -11.0%
H
3.3
4.6
|
L
 -10.3%
H
3.3
4.6
|
L
 -79.6%
H
0.1
22.6
|
L
 -89.9%
H
0.1
101.2
|
L
 -96.2%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc ADR |
|
3,921.7
|
112.4
|
L
 6.1%
H
107
115.4
|
L
 21.1%
H
90.8
115.4
|
L
 51.8%
H
72.7
115.4
|
L
 71.0%
H
60
115.4
|
L
 67.2%
H
49
115.4
|
L
 302.9%
H
11
115.4
|
L
H
6
115.4
|
L
H
6
115.4
|
| Neuphoria Therapeutics Inc |
|
10.3
|
4.4
|
L
 -3.7%
H
4.3
4.6
|
L
 -29.8%
H
4.3
6.0
|
L
 -70.1%
H
3.8
21.4
|
L
 -45.6%
H
3.8
21.4
|
L
 2090%
H
0.2
21.4
|
L
 -45.3%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE ADR |
|
24,997.7
|
104.0
|
L
 0.1%
H
101.7
109.0
|
L
 -1.6%
H
101.7
109.0
|
L
 -0.5%
H
101
109.7
|
L
 -3.2%
H
90.1
115.5
|
L
 -6.8%
H
81.2
129.3
|
L
 -26.5%
H
76.5
189.0
|
L
 19.4%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharmaceuticals ADR |
|
-
|
1.3
|
L
 -9.3%
H
1.2
1.6
|
L
 -13.0%
H
1.2
1.6
|
L
 -6.6%
H
1.2
1.6
|
L
 -13.6%
H
1.2
2.0
|
L
 -56.4%
H
1.2
6.2
|
L
 -84.5%
H
0.6
99
|
L
 -95.3%
H
0.6
99
|
L
 -96.9%
H
0.6
620
|
| Cabaletta Bio Inc |
|
275.3
|
3.0
|
L
 -16.6%
H
2.8
3.6
|
L
 21.9%
H
2.4
3.7
|
L
 19.0%
H
2.2
3.7
|
L
 109.0%
H
1.3
3.7
|
L
 -18.9%
H
1.0
5.5
|
L
 52.0%
H
1.0
26.4
|
L
 -73.7%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
41.8
|
3.0
|
L
 1.0%
H
3.0
3.0
|
L
 -0.7%
H
3.0
3.1
|
L
 -2.0%
H
3.0
3.7
|
L
 1.7%
H
2.3
3.7
|
L
 -14.8%
H
1.4
4.3
|
L
 -78.1%
H
1
14.6
|
L
 -98.5%
H
1
530.3
|
L
H
1
530.3
|
| Capricor Therapeutics Inc |
|
277.5
|
6.1
|
L
 -6.8%
H
6.1
6.5
|
L
 -2.1%
H
6.1
7.1
|
L
 -23.8%
H
6.0
7.9
|
L
 -23.2%
H
5.7
9.4
|
L
 -68.8%
H
5.7
20.8
|
L
 19.5%
H
2.7
23.4
|
L
 52.5%
H
2.6
23.4
|
L
 -85.1%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
42.3
|
4.5
|
L
 -3.0%
H
4.4
4.8
|
L
 -9.3%
H
4.4
5
|
L
 -87.9%
H
4.4
43.7
|
L
 -82.8%
H
4.4
43.7
|
L
 -57.8%
H
4.4
43.7
|
L
 -98.6%
H
4.4
461.2
|
L
 -99.0%
H
4.4
1067.3
|
L
 -99.2%
H
4.4
1067.3
|
| CASI Pharmaceuticals Inc |
|
21.5
|
1.4
|
L
 -3.5%
H
1.4
1.5
|
L
 -15.2%
H
1.3
1.7
|
L
 -20.6%
H
1.3
2.1
|
L
 7.8%
H
1.2
3.1
|
L
 -76.9%
H
1.1
6.3
|
L
 -30.2%
H
1.1
8.5
|
L
 -93.2%
H
1.1
39
|
L
 -89.2%
H
1.1
88.9
|
| Crescent Biopharma Inc |
|
-
|
12.4
|
L
 -3.1%
H
12
12.7
|
L
 -2.7%
H
12
13.3
|
L
 2.7%
H
9.8
13.3
|
L
 2.9%
H
9.8
15.8
|
L
 8.8%
H
7.6
21.4
|
L
 139.3%
H
2.8
21.4
|
L
 -8.7%
H
0.9
21.4
|
L
 -91.5%
H
0.9
167.3
|
| C4 Therapeutics Inc |
|
230.8
|
2.5
|
L
 -5.0%
H
2.4
2.7
|
L
 1.2%
H
2.4
2.8
|
L
 12.2%
H
2.0
2.8
|
L
 17.0%
H
2.0
3.7
|
L
 -55.8%
H
1.1
6.5
|
L
 -74.4%
H
1.1
11.9
|
L
 -90.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Cidara Therapeutics Inc |
|
2,605.0
|
102.7
|
L
 -6.0%
H
102.3
109.4
|
L
 10.3%
H
94.5
113
|
L
 4.3%
H
93
121.2
|
L
 63.3%
H
56.5
121.2
|
L
 684.8%
H
12.7
121.2
|
L
 -55.8%
H
10
840
|
L
 -89.6%
H
10
1260
|
L
 -98.2%
H
10
7228
|
| Niagen Bioscience Inc |
|
576.6
|
7.2
|
L
 -4.1%
H
7.1
7.7
|
L
 -4.5%
H
7.0
7.7
|
L
 -2.0%
H
6.8
7.8
|
L
 -20.0%
H
6.8
11.3
|
L
 23.4%
H
5.2
14.7
|
L
 332.9%
H
1.3
14.7
|
L
 62.8%
H
1.2
23.7
|
L
 68.1%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
461.4
|
7.8
|
L
 -9.8%
H
7.8
8.8
|
L
 0.6%
H
7.6
8.8
|
L
 35.8%
H
5.7
9.2
|
L
 1.8%
H
5.7
9.2
|
L
 -50.5%
H
5.7
17.5
|
L
 -39.6%
H
5.7
30.2
|
L
H
5.7
59.9
|
L
H
5.7
59.9
|
| Compugen |
|
161.8
|
1.7
|
L
 -2.3%
H
1.7
1.8
|
L
 -3.9%
H
1.6
1.8
|
L
 -1.7%
H
1.6
2.4
|
L
 16.9%
H
1.3
2.4
|
L
 1.2%
H
1.1
2.7
|
L
 88.0%
H
0.5
3.0
|
L
 -86.4%
H
0.5
15.2
|
L
 -73.4%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
144.7
|
1.6
|
L
 -8.4%
H
1.6
1.8
|
L
 -5.2%
H
1.5
1.8
|
L
 14.7%
H
1.4
2.1
|
L
 144.8%
H
0.6
3.8
|
L
 248.9%
H
0.2
3.8
|
L
 -7.9%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
186.0
|
1.6
|
L
 -4.8%
H
1.6
1.7
|
L
 -3.0%
H
1.6
1.8
|
L
 -3.6%
H
1.6
1.9
|
L
 81.8%
H
0.8
1.9
|
L
 122.2%
H
0.7
2.4
|
L
 -81.2%
H
0.7
11.0
|
L
 -90.4%
H
0.7
22.2
|
L
 -94.4%
H
0.7
32.0
|
| Cingulate Inc |
|
21.3
|
3.8
|
L
 0.3%
H
3.6
3.8
|
L
 -1.6%
H
3.5
3.9
|
L
 -6.4%
H
3.5
4.4
|
L
 -25.5%
H
3.5
5.7
|
L
 -1.3%
H
3.0
6.0
|
L
 251.9%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
120.6
|
12.0
|
L
 -4.2%
H
11.0
13.5
|
L
 43.7%
H
8.1
13.5
|
L
 49.6%
H
7.7
13.5
|
L
 243.3%
H
3.5
13.5
|
L
 96.1%
H
2.3
13.5
|
L
 -42.4%
H
2.3
39.8
|
L
 2118.5%
H
0.5
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
10.5
|
3.3
|
L
 -2.7%
H
3.2
3.4
|
L
 -17.5%
H
3.2
3.9
|
L
 -43.1%
H
3.2
6.5
|
L
 -30.1%
H
3.2
6.5
|
L
 -94.6%
H
3.2
66
|
L
 -94.6%
H
3.2
133.5
|
L
 -99.0%
H
3.2
894
|
L
 -100.0%
H
3.2
59100
|
| Clearside Biomedical Inc |
|
21.4
|
4.1
|
L
 0.5%
H
3.9
4.2
|
L
 4.9%
H
3.6
4.2
|
L
 0.5%
H
3.6
4.5
|
L
 -29.0%
H
3.3
7.1
|
L
 -73%
H
3.3
17.4
|
L
 -79.8%
H
3.3
31.8
|
L
 -80.4%
H
3.3
116.0
|
L
H
3.3
376.2
|
| Clearmind Medicine Inc |
|
4.4
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -19.8%
H
0.8
1.2
|
L
 -20.6%
H
0.8
1.2
|
L
 -16.5%
H
0.8
1.3
|
L
 -40.4%
H
0.8
2.2
|
L
 -89.7%
H
0.1
7.9
|
L
 -31.9%
H
0.1
21.9
|
L
H
0.1
21.9
|
| Compass Therapeutics Inc |
|
641.7
|
3.7
|
L
H
3.7
4.0
|
L
 -5.8%
H
3.6
4.3
|
L
 7.8%
H
3.4
4.9
|
L
 26.8%
H
2.7
4.9
|
L
 120%
H
1.3
4.9
|
L
 -1.1%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharmaceuticals Inc |
|
4.1
|
7.2
|
L
 -6.9%
H
7.2
7.5
|
L
 -13.1%
H
7.2
8.7
|
L
 -19.3%
H
7.2
10.6
|
L
 -6.9%
H
4.9
10.6
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
9900000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
96.9
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -14.3%
H
1.1
1.3
|
L
 8%
H
1.0
1.6
|
L
 52.1%
H
0.7
1.6
|
L
 -52.4%
H
0.5
2.3
|
L
 -10.7%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.2
|
1.1
|
L
H
1.1
1.1
|
L
 -7.6%
H
1.1
1.3
|
L
 -10.7%
H
1.0
1.3
|
L
 -41.1%
H
1.0
2.7
|
L
 -37.0%
H
1.0
3.3
|
L
 -60.9%
H
1.0
3.3
|
L
 -88.6%
H
1.0
41.5
|
L
 -99.6%
H
1.0
331.2
|
| CoDiagnostics Inc |
|
19.3
|
0.4
|
L
 -13.0%
H
0.4
0.5
|
L
 14.3%
H
0.4
1.6
|
L
 11.1%
H
0.3
1.6
|
L
 60%
H
0.2
1.6
|
L
 -66.9%
H
0.2
1.6
|
L
 -88.6%
H
0.2
3.8
|
L
 -97.0%
H
0.2
20.7
|
L
H
0.2
31.0
|
| Coeptis Therapeutics Holdings |
|
74.4
|
15.4
|
L
 1.4%
H
15.0
15.5
|
L
 2.9%
H
14.5
15.5
|
L
 -7.2%
H
14.5
18.2
|
L
 43.9%
H
10.5
19.2
|
L
 289.7%
H
2.3
19.2
|
L
 -83.4%
H
2.3
99.6
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
2,165.4
|
15.5
|
L
 -4.9%
H
15.5
16.8
|
L
 2.5%
H
15.5
16.8
|
L
 5.1%
H
14.2
17.2
|
L
 36.0%
H
10.4
17.2
|
L
 32.3%
H
3.7
17.2
|
L
 27.7%
H
3.7
17.2
|
L
 30.0%
H
3.7
18.1
|
L
H
1.2
70.6
|
| Collegium Pharmaceutical Inc |
|
1,137.2
|
36.1
|
L
 0.3%
H
35.2
36.6
|
L
 2.3%
H
33.9
36.6
|
L
 5.3%
H
31.3
36.6
|
L
 20.1%
H
29.7
40.0
|
L
 7.9%
H
23.2
40.0
|
L
 104.8%
H
16.9
42.3
|
L
 99.4%
H
14.0
42.3
|
L
 76.5%
H
7.4
42.3
|
| Corcept Therapeutics Inc |
|
7,815.4
|
74.2
|
L
 1.0%
H
70.5
74.3
|
L
 2.3%
H
70.5
74.8
|
L
 -13.2%
H
69.4
91
|
L
 7.5%
H
66.5
91
|
L
 55.8%
H
47.6
117.3
|
L
 157.2%
H
17.9
117.3
|
L
 326.0%
H
15.8
117.3
|
L
 1731.4%
H
3.2
117.3
|
| Cosmos Health Inc |
|
24.2
|
0.8
|
L
 -3.7%
H
0.8
0.8
|
L
 -23.5%
H
0.8
1.1
|
L
 -29.7%
H
0.8
1.3
|
L
 -9.3%
H
0.6
1.3
|
L
 8.3%
H
0.3
1.3
|
L
 -62.1%
H
0.3
23.8
|
L
 -99.2%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
| Cumberland Pharmaceuticals Inc |
|
41.3
|
2.8
|
L
 -7.7%
H
2.6
3.0
|
L
 -20.9%
H
2.6
3.5
|
L
 -14.8%
H
2.6
3.7
|
L
 -21.6%
H
2.6
4.2
|
L
 146.4%
H
1.0
7.3
|
L
 8.7%
H
1.0
7.3
|
L
 -6.1%
H
1.0
7.5
|
L
 -56.3%
H
1.0
8.0
|
| Catalyst Pharmaceuticals Inc |
|
2,624.1
|
21.4
|
L
 0.8%
H
21.0
21.7
|
L
 2.3%
H
20.7
21.7
|
L
 2.9%
H
19.9
21.7
|
L
 1.5%
H
19.1
22.5
|
L
 -2.1%
H
19.1
26.6
|
L
 58.5%
H
11.1
26.6
|
L
 621.9%
H
3.0
26.6
|
L
 541.9%
H
0.5
26.6
|
| Corbus Pharmaceuticals |
|
150.7
|
12.3
|
L
 1.2%
H
11.6
12.5
|
L
 -27.1%
H
11.6
18.1
|
L
 -5.5%
H
11.6
20.6
|
L
 32.1%
H
8.4
20.6
|
L
 -27.3%
H
4.6
20.8
|
L
 223.7%
H
2.1
61.9
|
L
 -59.8%
H
2.1
120
|
L
 -75.3%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
226.3
|
2.4
|
L
 0.4%
H
2.4
3.5
|
L
 -2.4%
H
2.3
3.5
|
L
 9.0%
H
2.2
3.5
|
L
 24.6%
H
1.6
3.5
|
L
 10.0%
H
0.7
3.5
|
L
 -74.3%
H
0.7
10.7
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc |
|
104.6
|
1.1
|
L
 -2.7%
H
1.1
1.2
|
L
 -7.6%
H
1.1
1.2
|
L
 4.8%
H
1.0
1.4
|
L
 -20.3%
H
0.9
1.4
|
L
 -41.2%
H
0.8
2.2
|
L
 80.3%
H
0.5
3.1
|
L
 -63.0%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
18.5
|
1.5
|
L
 -0.7%
H
1.5
1.6
|
L
 -8.1%
H
1.5
1.7
|
L
 -8.1%
H
1.4
1.7
|
L
 -9.2%
H
1.4
2.0
|
L
 -64.6%
H
1.0
5
|
L
 -91.4%
H
1.0
20
|
L
 -93.5%
H
1.0
348
|
L
 -99.3%
H
1.0
372
|
| CorMedix Inc |
|
904.1
|
11.5
|
L
 3.7%
H
10.9
11.6
|
L
 3.3%
H
10.9
11.9
|
L
 4.4%
H
9.9
12.6
|
L
 -0.9%
H
9.6
15.0
|
L
 15.5%
H
5.6
17.4
|
L
 291.2%
H
2.6
17.4
|
L
 130.8%
H
2.6
18.8
|
L
 -15.1%
H
0.9
22.7
|
| Crinetics Pharmaceuticals Inc |
|
4,035.4
|
42.9
|
L
 -1.5%
H
42.1
43.3
|
L
 4.5%
H
41.1
44.7
|
L
 3.2%
H
39.9
46.1
|
L
 53.9%
H
25.8
47.4
|
L
 -24.4%
H
24.1
62.5
|
L
 137.9%
H
15.2
62.5
|
L
 247.0%
H
12.0
62.5
|
L
H
10.6
62.5
|
| Cronos Group Inc |
|
972.7
|
2.5
|
L
 1.2%
H
2.5
2.6
|
L
 0.8%
H
2.4
2.6
|
L
 -1.9%
H
2.4
2.8
|
L
 30.3%
H
1.9
3.2
|
L
 17.6%
H
1.6
3.2
|
L
 -14.5%
H
1.6
3.6
|
L
 -57.7%
H
1.6
15.8
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
5,636.2
|
62.0
|
L
 -3.2%
H
60.5
64.7
|
L
 -8.3%
H
60.5
67.7
|
L
 -14.9%
H
60.5
78.5
|
L
 10.5%
H
50.8
78.5
|
L
 22.1%
H
30.0
78.5
|
L
 13.3%
H
30.0
91.1
|
L
 -28.1%
H
30.0
220.2
|
L
H
11.6
220.2
|
| Corvus Pharmaceuticals Inc |
|
572.3
|
7.7
|
L
 -4.5%
H
7.5
8.0
|
L
 4.5%
H
7.4
8.4
|
L
 9.1%
H
6.4
8.4
|
L
 87.3%
H
4.1
8.4
|
L
 -15.6%
H
2.5
10
|
L
 793.0%
H
0.6
10
|
L
 96.9%
H
0.6
10
|
L
H
0.6
22.1
|
| Champions Oncology Inc |
|
93.8
|
6.8
|
L
 -0.6%
H
6.7
6.9
|
L
 -1.3%
H
6.7
6.9
|
L
 6.4%
H
6.3
7
|
L
 10.4%
H
6.0
8.7
|
L
 70%
H
4.0
12.0
|
L
 -2.9%
H
3.6
12.0
|
L
 -19.0%
H
3.6
14.7
|
L
 24.5%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
648.1
|
3.9
|
L
 10.1%
H
3.5
4.2
|
L
 20.6%
H
3.2
4.2
|
L
 19.8%
H
3.1
4.2
|
L
 67.2%
H
1.7
4.2
|
L
 274.3%
H
0.4
4.2
|
L
 209.4%
H
0.4
5.9
|
L
 -40.1%
H
0.4
10.1
|
L
 -64.9%
H
0.4
35
|
| Cue Biopharma Inc |
|
55.3
|
0.7
|
L
 -6.5%
H
0.7
0.8
|
L
 -7.7%
H
0.7
0.8
|
L
H
0.7
1.0
|
L
 -2.7%
H
0.7
1.0
|
L
 -52.6%
H
0.5
2.0
|
L
 -76%
H
0.5
5.1
|
L
 -93.6%
H
0.5
18.4
|
L
H
0.5
31.7
|
| CureVac NV |
|
1,202.4
|
5.3
|
L
H
5.3
5.4
|
L
 -0.4%
H
5.3
5.4
|
L
 -0.9%
H
5.3
5.5
|
L
 -1.3%
H
5.3
5.5
|
L
 93.5%
H
2.4
5.7
|
L
 -25.6%
H
2.2
12.8
|
L
 -88.7%
H
2.2
151.8
|
L
H
2.2
151.8
|
| Cadrenal Therapeutics Inc |
|
27.6
|
13.5
|
L
 -1.2%
H
13.1
13.6
|
L
 -4.6%
H
12.7
14.2
|
L
 -4.9%
H
12.1
14.6
|
L
 30.6%
H
8.7
14.6
|
L
 -25.0%
H
8.7
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Bio Green Med Solution Inc |
|
4.2
|
1.9
|
L
 4.5%
H
1.7
2.0
|
L
 1.1%
H
1.6
2.3
|
L
 -59.0%
H
1.6
6.7
|
L
 -80.9%
H
1.6
10.6
|
L
 -98.8%
H
1.6
213.6
|
L
 -100.0%
H
1.6
5184
|
L
 -100.0%
H
1.6
41112
|
L
 -100.0%
H
1.6
907200
|
| Cyclerion Therapeutics Inc |
|
6.0
|
1.9
|
L
 -0.5%
H
1.7
1.9
|
L
 -12.3%
H
1.7
2.2
|
L
 -25%
H
1.7
2.6
|
L
 -28.2%
H
1.7
3.8
|
L
 -36.5%
H
1.3
8.4
|
L
 -83.4%
H
1.3
19.7
|
L
 -96.1%
H
1.3
138
|
L
H
1.3
457
|
| Cytokinetics Inc |
|
7,183.0
|
60.0
|
L
 -5.6%
H
59.1
64.0
|
L
 3.8%
H
57.8
64.1
|
L
 6.6%
H
54.3
64.1
|
L
 63.6%
H
32.9
64.1
|
L
 15.8%
H
29.3
64.1
|
L
 43.4%
H
26.0
110
|
L
 276.4%
H
15.2
110
|
L
 481.1%
H
5.8
110
|
| Cellectis ADR |
|
328.1
|
3.3
|
L
 -5.2%
H
3.2
3.4
|
L
 -6.0%
H
3.2
3.8
|
L
 -4.4%
H
3.2
5.5
|
L
 10.9%
H
2.5
5.5
|
L
 81.7%
H
1.1
5.5
|
L
 29.2%
H
1.0
5.5
|
L
 -79.4%
H
1.0
34.7
|
L
 -89.6%
H
1.0
45.3
|
| Chemomab Therapeutics ADR |
|
14.5
|
2.8
|
L
 -8.5%
H
2.8
3.1
|
L
 -13.9%
H
2.8
3.4
|
L
 3.7%
H
2.7
3.6
|
L
 -31.7%
H
2.4
4.2
|
L
 -49.3%
H
2.4
9.8
|
L
 -65.7%
H
1.7
21.4
|
L
 -96.3%
H
1.7
675.2
|
L
H
1.7
736
|
| Compass Pathways Plc ADR |
|
570.9
|
6.0
|
L
 -5.9%
H
5.8
6.3
|
L
 -5.3%
H
5.8
6.9
|
L
 -1%
H
5.8
7.1
|
L
 37.1%
H
4.0
7.1
|
L
 25.3%
H
2.3
7.1
|
L
 -39.3%
H
2.3
12.8
|
L
 -81.7%
H
2.3
61.7
|
L
H
2.3
61.7
|
| Centessa Pharmaceuticals plc |
|
3,209.7
|
23.9
|
L
 -3.9%
H
23.5
25.4
|
L
 -0.9%
H
23.5
25.4
|
L
 3.9%
H
21.8
25.4
|
L
 42.4%
H
15.0
25.4
|
L
 52.8%
H
9.6
25.4
|
L
 482.5%
H
3
25.4
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
| Connect Biopharma Holdings |
|
91.9
|
1.7
|
L
 -3.5%
H
1.6
1.7
|
L
 -2.9%
H
1.5
1.7
|
L
 18.7%
H
1.4
2.1
|
L
 -17.5%
H
1.2
2.5
|
L
 39.8%
H
0.5
2.9
|
L
 98.8%
H
0.5
2.9
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
25.9
|
1.9
|
L
 -2.0%
H
1.9
2.0
|
L
 -9%
H
1.9
2.1
|
L
 -10.7%
H
1.9
2.3
|
L
 -20.7%
H
1.8
2.5
|
L
 -53.9%
H
1.8
9.2
|
L
 -84.2%
H
0.3
16.8
|
L
 -83.6%
H
0.3
46.2
|
L
 -99.6%
H
0.3
519.6
|
| Day One Biopharmaceuticals Inc |
|
748.8
|
7.3
|
L
 -1.8%
H
7.2
7.6
|
L
 -2.4%
H
6.9
7.9
|
L
 -1.6%
H
6.9
8.3
|
L
 9.9%
H
5.6
8.3
|
L
 -50.1%
H
5.6
16.8
|
L
 -62.5%
H
5.6
25.8
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
224.2
|
8.5
|
L
 4.9%
H
8.0
8.7
|
L
 14.2%
H
7.4
8.7
|
L
 16.7%
H
6.9
8.7
|
L
 21.9%
H
6.7
8.9
|
L
 38.1%
H
3.5
8.9
|
L
 283.8%
H
1.0
8.9
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharmaceuticals Inc |
|
-
|
7.0
|
L
 -0.4%
H
6.8
7.2
|
L
 -0.7%
H
6.7
7.5
|
L
 -14.1%
H
6.7
9.7
|
L
 -20.5%
H
6.7
11.3
|
L
 -20.1%
H
5.5
13.1
|
L
 -4.4%
H
4.1
14.4
|
L
 -88.6%
H
4.1
138.8
|
L
 -99.9%
H
4.1
29250
|
| DiaMedica Therapeutics Inc |
|
351.5
|
6.8
|
L
 -3.7%
H
6.7
7.2
|
L
 -1.2%
H
6.6
7.2
|
L
 -2.9%
H
6.5
7.2
|
L
 65.1%
H
4.2
7.5
|
L
 60%
H
3.2
7.5
|
L
 462.0%
H
1.1
7.5
|
L
 54.5%
H
1.1
10.9
|
L
 288.6%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
2,245.8
|
15.4
|
L
 -5.7%
H
15
16.3
|
L
 -3.8%
H
15
17.0
|
L
 1.1%
H
14.0
17.7
|
L
 14.3%
H
12.6
17.7
|
L
 -43.2%
H
10.6
33.3
|
L
 -50.0%
H
10.6
33.3
|
L
 -64.9%
H
10.6
93.9
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
75.7
|
4.9
|
L
 -4.7%
H
4.8
5.1
|
L
 -16.9%
H
4.8
6.2
|
L
 -27.4%
H
4.8
7.5
|
L
 8.2%
H
4.5
8.4
|
L
 189.9%
H
0.8
13.6
|
L
 -14.9%
H
0.8
13.6
|
L
 -41.4%
H
0.8
43.4
|
L
 -98.7%
H
0.8
577.5
|
| DarioHealth Corp |
|
93.0
|
13.7
|
L
 -1.8%
H
13.3
14
|
L
 -15.1%
H
13.3
16.4
|
L
 -20.4%
H
12.2
17.7
|
L
 24.9%
H
5.9
17.7
|
L
 -27.5%
H
5.9
31
|
L
 -83.4%
H
5.9
135.6
|
L
 -93.7%
H
5.9
637
|
L
 -99.5%
H
5.9
4669.9
|
| Dermata Therapeutics Inc |
|
2.3
|
3.4
|
L
H
3.2
3.4
|
L
 -14.7%
H
3.2
4.3
|
L
 -30.4%
H
3.2
5.9
|
L
 -47.0%
H
3.2
7.1
|
L
 180.3%
H
0.6
7.1
|
L
 -67.1%
H
0.2
12.2
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
364.8
|
51.5
|
L
 -6.0%
H
51
56
|
L
 -15.9%
H
51
63.7
|
L
 -8.1%
H
48.9
70.2
|
L
 53.0%
H
32.5
70.2
|
L
 8.3%
H
23.2
70.2
|
L
 999.6%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
| Design Therapeutics Inc |
|
373.0
|
6.6
|
L
 -2.2%
H
6.3
6.7
|
L
 14.3%
H
5.7
7.1
|
L
 8.8%
H
5.3
7.2
|
L
 71.5%
H
3.9
7.6
|
L
 26.0%
H
2.6
7.8
|
L
 -57.7%
H
1.9
16.6
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
86.8
|
7.4
|
L
 -9.8%
H
6.2
7.7
|
L
 9.5%
H
6.2
8.8
|
L
 35.8%
H
5.3
8.8
|
L
 59.3%
H
4.2
8.8
|
L
 -18.6%
H
3.6
9.0
|
L
 429.5%
H
0.3
19.4
|
L
 19.7%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Technologies Corp |
|
1,195.0
|
10.2
|
L
 -0.7%
H
10.1
10.3
|
L
 -1.8%
H
10.1
10.6
|
L
 0.9%
H
9.7
10.6
|
L
 -6.2%
H
9.2
12.1
|
L
 -13.5%
H
9.2
14.6
|
L
 -9.6%
H
9.2
15.2
|
L
 171.0%
H
3.7
21.4
|
L
 -58.5%
H
1.8
29.9
|
| Dyne Therapeutics Inc |
|
3,430.0
|
24.1
|
L
 6.8%
H
21.8
24.3
|
L
 40.8%
H
21.8
25
|
L
 92.1%
H
12.4
25
|
L
 139.9%
H
9.9
25
|
L
 -16.1%
H
6.4
35.7
|
L
 134.5%
H
6.4
47.5
|
L
 14.3%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Technologies ADR |
|
481.5
|
14.3
|
L
 -2.7%
H
13.7
14.6
|
L
 -7.5%
H
13.7
16.9
|
L
 16.3%
H
12.5
18
|
L
 58.3%
H
8.7
18
|
L
 274.0%
H
0.5
18
|
L
 -3.1%
H
0.5
23.7
|
L
 -19.0%
H
0.5
73.8
|
L
 -96.1%
H
0.5
505.7
|
| Editas Medicine Inc |
|
275.2
|
3.1
|
L
 -0.7%
H
2.9
3.1
|
L
 -17.7%
H
2.9
3.6
|
L
 -21.3%
H
2.9
4.5
|
L
 25.4%
H
2.1
4.5
|
L
 5.2%
H
0.9
4.5
|
L
 -76.3%
H
0.9
13.9
|
L
 -90.2%
H
0.9
100.0
|
L
H
0.9
100.0
|
| Edesa Biotech Inc |
|
12.8
|
1.7
|
L
 -6.5%
H
1.7
2.0
|
L
 -36.5%
H
1.7
2.7
|
L
 -36.7%
H
1.7
3.0
|
L
 -18.7%
H
1.7
3.0
|
L
 -45.6%
H
1.6
4.5
|
L
 -75.1%
H
1.6
19.7
|
L
 -95.9%
H
1.6
84
|
L
 -99.9%
H
1.6
2646
|
| Eledon Pharmaceuticals Inc |
|
261.1
|
4.4
|
L
 0.9%
H
4.1
4.6
|
L
 25.3%
H
3.4
4.6
|
L
 58.0%
H
2.6
4.6
|
L
 29.0%
H
2.3
4.6
|
L
 -11.6%
H
2.3
5.4
|
L
 73.7%
H
1.1
5.4
|
L
 -81.1%
H
1.1
26.4
|
L
 -99.8%
H
1.1
2094.7
|
| Elicio Therapeutics Inc |
|
151.1
|
9.3
|
L
 -0.4%
H
9
9.5
|
L
 -4.6%
H
9
10.2
|
L
 -16.4%
H
9
11.5
|
L
 -7.3%
H
8.5
12.6
|
L
 101.5%
H
4.2
12.6
|
L
 -4.6%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,184.7
|
20
|
L
 -14.6%
H
18.3
23.3
|
L
 -3.0%
H
18.3
24.6
|
L
 0.4%
H
18.3
24.6
|
L
 6.8%
H
17.4
24.6
|
L
 -27.6%
H
13.3
29.8
|
L
 16.6%
H
9.8
30.0
|
L
 -69.6%
H
3.9
119.7
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
135.5
|
2
|
L
 -2.4%
H
1.9
2.1
|
L
 0.5%
H
1.9
2.2
|
L
 -2.0%
H
1.5
2.5
|
L
 37.9%
H
1.5
2.6
|
L
 -48.9%
H
1.1
4.3
|
L
 -33.8%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics |
|
25.5
|
1.1
|
L
H
1.0
1.1
|
L
 -0.9%
H
1.0
1.2
|
L
 1.0%
H
1.0
1.2
|
L
 -27.6%
H
1.0
2.1
|
L
 -22.8%
H
0.8
2.1
|
L
 -75.4%
H
0.8
4.9
|
L
 -90.8%
H
0.8
29.4
|
L
 -99.5%
H
0.8
318
|
| Enochian Biosciences Inc |
|
-
|
0.9
|
L
H
0.8
0.9
|
L
 -19.4%
H
0.8
1.1
|
L
 -38.7%
H
0.8
1.4
|
L
 234.6%
H
0.1
1.4
|
L
 171.9%
H
0.1
1.4
|
L
 -53.7%
H
0.1
2.3
|
L
 -72.5%
H
0.1
13.8
|
L
 -78.3%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
6.4
|
2.2
|
L
 -1.4%
H
2.1
2.2
|
L
 -3.6%
H
2.0
2.3
|
L
 -12.2%
H
2.0
2.8
|
L
 4.9%
H
2.0
2.8
|
L
 230.8%
H
0.4
9.9
|
L
 -93.7%
H
0.1
56.5
|
L
 -99.9%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Enanta Pharmaceuticals Inc |
|
312.2
|
10.8
|
L
 -1.3%
H
10.4
11.2
|
L
 3.0%
H
10.3
11.5
|
L
 4.7%
H
10.1
12.0
|
L
 52.2%
H
6.5
15.3
|
L
 -1.2%
H
4.1
15.3
|
L
 -75.2%
H
4.1
62.1
|
L
 -75.6%
H
4.1
102
|
L
 -66.2%
H
4.1
127.8
|
| Entera Bio |
|
129.7
|
2.8
|
L
 -2.4%
H
2.8
3.0
|
L
 27.9%
H
2.2
3.0
|
L
 51.1%
H
1.8
3.0
|
L
 45.6%
H
1.8
3.0
|
L
 57.8%
H
1.5
3.0
|
L
 305.7%
H
0.5
3.4
|
L
 167.9%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
3.7
|
7.1
|
L
 24.2%
H
5.7
8.6
|
L
 -6.1%
H
5.6
8.6
|
L
 -24.0%
H
5.6
11.4
|
L
 -48.7%
H
5.6
17.6
|
L
 -91.8%
H
5.6
93.6
|
L
 -98.8%
H
5.6
1256.4
|
L
 -100.0%
H
5.6
135360
|
L
 -100.0%
H
5.6
12150000
|
| Evolus Inc |
|
413.3
|
6.4
|
L
 -1.1%
H
6.2
6.5
|
L
 -5.9%
H
6.1
7.4
|
L
 2.4%
H
5.9
7.4
|
L
 -30.2%
H
5.7
9.4
|
L
 -61.9%
H
5.7
17.4
|
L
 -23.0%
H
5.7
17.8
|
L
 112.3%
H
3.1
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
55.4
|
1.6
|
L
 9.9%
H
1.4
1.6
|
L
 9.9%
H
1.3
1.6
|
L
 5.4%
H
1.2
1.6
|
L
 118.3%
H
0.5
2.4
|
L
 86.8%
H
0.3
2.4
|
L
 -10.4%
H
0.3
3.3
|
L
 -70.6%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Erasca Inc |
|
675.1
|
2.4
|
L
 -1.7%
H
2.3
2.5
|
L
H
2.3
2.5
|
L
 11.7%
H
2.1
2.8
|
L
 71.2%
H
1.3
2.8
|
L
 -12.5%
H
1.0
3.3
|
L
 -67.5%
H
1.0
9.3
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
683.3
|
3.0
|
L
 -0.7%
H
2.9
3
|
L
 8.9%
H
2.7
3.1
|
L
 1.7%
H
2.3
3.4
|
L
 110.7%
H
1.4
3.4
|
L
 45.3%
H
0.7
3.9
|
L
 -63.3%
H
0.7
8.9
|
L
 -89.8%
H
0.7
39.5
|
L
 -88.9%
H
0.7
82.7
|
| Eton Pharmaceuticals Inc |
|
481.6
|
18.0
|
L
 -0.3%
H
17.5
18.2
|
L
 -2.7%
H
17.5
18.9
|
L
 -9.3%
H
17.5
21.9
|
L
 27.1%
H
14.0
23
|
L
 108.4%
H
8.2
23
|
L
 615.5%
H
2.4
23
|
L
 155.8%
H
2.0
23
|
L
H
2.0
23
|
| Evoke Pharma Inc |
|
7.2
|
4.6
|
L
 -10.9%
H
4.5
5.2
|
L
 -3.4%
H
4.5
5.2
|
L
 -0.4%
H
4.2
5.2
|
L
 -2.1%
H
4.2
7.0
|
L
 -20.9%
H
1.9
9.9
|
L
 -77.4%
H
0.4
71.5
|
L
 -99.2%
H
0.4
691.2
|
L
 -99.2%
H
0.4
1599.8
|
| Edgewise Therapeutics Inc |
|
1,893.1
|
18.0
|
L
 -1.7%
H
17.6
18.6
|
L
 18.4%
H
15.2
18.8
|
L
 19.8%
H
14.3
18.8
|
L
 25.6%
H
12.3
18.8
|
L
 -47.2%
H
10.6
38.1
|
L
 91.2%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
10,245.8
|
38.1
|
L
 -1.6%
H
36
38.4
|
L
 -1.7%
H
36
40.6
|
L
 -8.0%
H
33.8
41.5
|
L
 2.2%
H
33.8
41.8
|
L
 11.6%
H
31.9
49.6
|
L
 123.8%
H
15.3
49.6
|
L
 84.7%
H
14.9
49.6
|
L
 518.9%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
58.4
|
5.9
|
L
 -8.6%
H
5.8
6.5
|
L
 -23.5%
H
5.8
9.1
|
L
 -50.0%
H
5.8
11.9
|
L
 -16.4%
H
5.1
15
|
L
 -85.5%
H
0.0
43.2
|
L
 -96.4%
H
0.0
468
|
L
 -97.7%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharmaceuticals Inc |
|
1,005.4
|
12.5
|
L
 -4.9%
H
12.2
13.3
|
L
 3.9%
H
11.6
13.3
|
L
 -7.8%
H
11.2
14.4
|
L
 28.2%
H
9.4
14.9
|
L
 3.2%
H
3.9
14.9
|
L
 142.7%
H
2.2
31.0
|
L
 219.2%
H
2.2
31.0
|
L
 -67.7%
H
2.2
58.1
|
| Evaxion Biotech AS ADR |
|
45.7
|
5.8
|
L
 0.4%
H
5.5
6.0
|
L
 -2.0%
H
5.5
6.8
|
L
 21.7%
H
4.7
12.2
|
L
 121.1%
H
2.5
12.2
|
L
 122.8%
H
0.8
12.2
|
L
 -77.3%
H
0.8
26
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE ADR |
|
1,427.9
|
4.0
|
L
 -1.2%
H
4.0
4.1
|
L
 -2.0%
H
4.0
4.3
|
L
 3.6%
H
3.8
4.3
|
L
H
3.4
4.3
|
L
 3.6%
H
2.8
5.6
|
L
 -57.6%
H
2.8
13.5
|
L
 -69.7%
H
2.8
26.6
|
L
 81.1%
H
1.6
26.6
|
| Fate Therapeutics Inc |
|
145.3
|
1.3
|
L
 -6.7%
H
1.2
1.4
|
L
 -23.6%
H
1.2
1.9
|
L
 4.1%
H
1.1
1.9
|
L
 17.8%
H
0.9
1.9
|
L
 -48.2%
H
0.7
3.5
|
L
 -93.7%
H
0.7
24.0
|
L
 -97.1%
H
0.7
121.2
|
L
 -72.9%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
72.6
|
2.4
|
L
 -4.7%
H
2.4
2.6
|
L
 -2.8%
H
2.4
2.7
|
L
 -12.9%
H
2.4
3.2
|
L
 34.8%
H
1.8
4.2
|
L
 28.4%
H
1.3
4.2
|
L
 -80.6%
H
1.2
17.4
|
L
 -92.7%
H
1.2
91.5
|
L
 -94.4%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
146.5
|
11.8
|
L
 -9.0%
H
11.6
13.5
|
L
 -2.7%
H
11.6
15.1
|
L
 -12.4%
H
11.0
15.5
|
L
 22.6%
H
9.1
17
|
L
 181.8%
H
4.1
28
|
L
 -56.4%
H
4.1
32.3
|
L
 -98.8%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
524.0
|
11.2
|
L
 -2.4%
H
10.6
11.7
|
L
 -1.1%
H
10.6
12.3
|
L
 29.4%
H
8.1
12.3
|
L
 74.8%
H
5.1
12.3
|
L
 39.0%
H
2.2
12.3
|
L
 36%
H
2.2
36.3
|
L
H
2.2
55.1
|
L
H
2.2
55.1
|
| Fennec Pharmaceuticals Inc |
|
226.3
|
8.1
|
L
 -0.9%
H
8.0
8.3
|
L
 -9.6%
H
8.0
9.2
|
L
 -15.9%
H
8.0
9.9
|
L
 3.7%
H
7.2
9.9
|
L
 87.3%
H
4.0
9.9
|
L
 -1.5%
H
4.0
11.9
|
L
 10.9%
H
3.8
11.9
|
L
 502.2%
H
0.3
15.0
|
| FibroGen Inc |
|
44.5
|
11.0
|
L
 -1.0%
H
11
11.3
|
L
 1.7%
H
10.5
11.3
|
L
 -7.7%
H
10.3
12.1
|
L
 59.8%
H
6.7
12.6
|
L
 38.0%
H
4.5
22.0
|
L
 -97.3%
H
4.5
642.3
|
L
 -98.9%
H
4.5
1430.2
|
L
 -98.2%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
238.0
|
4.2
|
L
 -4.5%
H
4.1
4.5
|
L
 3.4%
H
3.9
4.7
|
L
 -7.3%
H
3.7
4.8
|
L
 -15.6%
H
3.7
5.9
|
L
 -46.5%
H
2.9
9.7
|
L
 -51.3%
H
2.7
10.2
|
L
 -73.6%
H
2.7
28.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
31.3
|
2.6
|
L
 -8.5%
H
2.6
2.9
|
L
 -13.5%
H
2.5
3.1
|
L
 24.2%
H
2.0
4.0
|
L
 28.5%
H
1.6
4.0
|
L
 -94.6%
H
1.3
51.3
|
L
 -90.3%
H
1.3
53.8
|
L
 -98.6%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Flora Growth Corp |
|
6.3
|
8.8
|
L
 -7.5%
H
8.7
9.5
|
L
 -33.7%
H
8.7
13.7
|
L
 -51.1%
H
8.7
20.5
|
L
 -55.7%
H
8.7
47
|
L
 -83.4%
H
8.7
81.9
|
L
 -97.9%
H
8.7
464.3
|
L
H
8.7
16731
|
L
H
8.7
16731
|
| Amicus Therapeutics Inc |
|
2,731.0
|
8.9
|
L
 -1.9%
H
8.6
9.1
|
L
 2.2%
H
8.6
9.3
|
L
 7.4%
H
7.9
9.3
|
L
 40.2%
H
6.3
9.3
|
L
 -22.8%
H
5.5
12.7
|
L
 -11.3%
H
5.5
14.6
|
L
 -50.1%
H
5.5
25.4
|
L
 1.6%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
36.8
|
L
 -10%
H
36.4
41.6
|
L
 -3.3%
H
36.0
42.7
|
L
 -19.5%
H
36.0
55.9
|
L
 165.9%
H
13.7
55.9
|
L
 143.7%
H
10.3
55.9
|
L
 -63.7%
H
9.2
279.5
|
L
 -96.5%
H
9.2
2918.5
|
L
H
9.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
487.9
|
9.0
|
L
 3.1%
H
8.5
9.5
|
L
 -2.2%
H
8.3
10.1
|
L
 -5.2%
H
8.3
10.1
|
L
 32.1%
H
6.3
10.1
|
L
 181%
H
2.3
10.1
|
L
 63.4%
H
2.3
15
|
L
 -2.7%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
6.3
|
4.0
|
L
 -4.9%
H
3.9
4.3
|
L
H
3.8
4.6
|
L
 -6.9%
H
3.8
5.8
|
L
 861.9%
H
0.4
5.8
|
L
 861.9%
H
0.4
5.8
|
L
 -96.9%
H
0.4
179.2
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
386.9
|
6
|
L
 3.3%
H
5.6
6.0
|
L
 14.7%
H
5.0
6.0
|
L
 41.2%
H
4.2
6.0
|
L
 64.4%
H
3.5
6.6
|
L
 140%
H
0.7
6.6
|
L
 341.2%
H
0.7
6.6
|
L
 133.5%
H
0.7
6.6
|
L
 109.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
66.1
|
1.8
|
L
 -6.1%
H
1.8
2.0
|
L
 -7.1%
H
1.7
2.1
|
L
 -1.1%
H
1.7
2.4
|
L
 27.8%
H
1.4
2.4
|
L
 -20.7%
H
1.4
2.8
|
L
 -42.1%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| Generation Bio Co |
|
35.5
|
5.3
|
L
 -4.4%
H
5.2
5.5
|
L
 -13.6%
H
5.2
6.1
|
L
 -14.2%
H
5.2
6.9
|
L
 25.2%
H
4.0
7.0
|
L
 -76.2%
H
3
25.7
|
L
 -90.1%
H
3
73.5
|
L
 -97.9%
H
3
557.2
|
L
H
3
557.2
|
| CytoMed Therapeutics |
|
24.9
|
2.1
|
L
 -3.6%
H
2.1
2.2
|
L
 -11.3%
H
2.1
2.5
|
L
 5.5%
H
1.9
3.7
|
L
 15.9%
H
1.7
3.7
|
L
 -7.8%
H
1.7
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
| Geron Corp |
|
765.6
|
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 -3.2%
H
1.2
1.3
|
L
 -13.0%
H
1.2
1.5
|
L
 2.6%
H
1.2
1.6
|
L
 -70.8%
H
1.1
4.5
|
L
 -44.2%
H
1.1
5.3
|
L
 -31.4%
H
1.0
5.3
|
L
 -67.4%
H
0.8
7.0
|
| GH Research PLC |
|
839.3
|
13.5
|
L
 -5.5%
H
13.4
14.8
|
L
 -3.0%
H
12.5
14.8
|
L
 1.4%
H
12.3
14.9
|
L
 -1.5%
H
11.3
15.0
|
L
 66.0%
H
6.7
20.5
|
L
 30.2%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
151,708.2
|
122.1
|
L
 1.9%
H
119.1
122.3
|
L
 0.9%
H
114.0
122.3
|
L
 10.4%
H
109.7
124.6
|
L
 7.8%
H
108.5
124.6
|
L
 36.4%
H
86.1
124.6
|
L
 56.7%
H
62.1
124.6
|
L
 108.5%
H
56.6
124.6
|
L
 11.4%
H
56.6
124.6
|
| Galmed Pharmaceuticals |
|
7.3
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 -2.9%
H
1.3
1.5
|
L
 -14.7%
H
1.3
1.7
|
L
 -13.6%
H
1.2
1.7
|
L
 -58.6%
H
1.2
3.6
|
L
 -98.1%
H
0.2
170.1
|
L
 -99.8%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
114.9
|
8.4
|
L
 -8.5%
H
8.4
9.2
|
L
 -15.6%
H
8.4
10.2
|
L
 -20.9%
H
8.4
11.5
|
L
 -24.0%
H
8.4
13
|
L
 -37.3%
H
8.1
15.5
|
L
 -4.3%
H
7.6
21.5
|
L
 140.2%
H
3.3
158.1
|
L
H
3.3
158.1
|
| Galecto Inc |
|
8.9
|
6.7
|
L
 -8.5%
H
6.7
7.6
|
L
 -20.5%
H
6.7
8.4
|
L
 69.6%
H
3.6
31.7
|
L
 109.4%
H
2.5
31.7
|
L
 -2.9%
H
2.0
31.7
|
L
 243.6%
H
0.5
31.7
|
L
 -55.3%
H
0.5
31.7
|
L
H
0.5
31.7
|
| Monte Rosa Therapeutics Inc |
|
745.4
|
12.1
|
L
 -6.1%
H
11.8
13.0
|
L
 8.4%
H
11.3
13.2
|
L
 58.2%
H
7.2
13.2
|
L
 152.0%
H
4.1
13.2
|
L
 35.6%
H
3.5
13.2
|
L
 49.8%
H
2.4
13.2
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
797.0
|
12.4
|
L
 -3.1%
H
12
12.7
|
L
 -2.7%
H
12
13.3
|
L
 2.7%
H
9.8
13.3
|
L
 2.9%
H
9.8
15.8
|
L
 -67.8%
H
9.8
44.8
|
L
 -82.6%
H
9.8
416
|
L
 -95.4%
H
9.8
440
|
L
 -98.2%
H
9.8
2605
|
| Genelux Corp |
|
311.3
|
8.2
|
L
 2.0%
H
7.8
8.5
|
L
 5.4%
H
7.0
8.5
|
L
 87.7%
H
4.4
8.5
|
L
 134.8%
H
3.0
8.5
|
L
 159.9%
H
2.0
8.5
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
5.3
|
5.3
|
L
 -8.2%
H
5.2
5.8
|
L
 -44.9%
H
5.2
9.9
|
L
 2550%
H
0.2
13.0
|
L
 2204.4%
H
0.1
13.0
|
L
 146.5%
H
0.1
13.0
|
L
 298.5%
H
0.1
13.0
|
L
 71.5%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
547.0
|
2.4
|
L
 -2.5%
H
2.4
2.5
|
L
 -3.6%
H
2.3
2.5
|
L
 -3.6%
H
2.1
2.6
|
L
 19.5%
H
1.7
3.6
|
L
 174.7%
H
0.7
3.6
|
L
 -77.5%
H
0.5
10.9
|
L
 -71.8%
H
0.5
15.2
|
L
H
0.5
27.2
|
| Geovax Labs Inc |
|
16.9
|
0.6
|
L
H
0.6
0.6
|
L
H
0.5
0.6
|
L
 1.8%
H
0.5
0.6
|
L
 -20.8%
H
0.5
0.8
|
L
 -70.3%
H
0.4
3.7
|
L
 -34.5%
H
0.3
11.1
|
L
 -80.6%
H
0.3
11.1
|
L
 -100.0%
H
0.3
1000000
|
| Graphite Bio Inc |
|
1,626.6
|
27.9
|
L
 -6.0%
H
27.1
29.6
|
L
 -12.6%
H
27.1
32.9
|
L
 -42.2%
H
27.1
49.9
|
L
 -6.8%
H
27.1
50.4
|
L
 4.2%
H
25.9
50.4
|
L
 -83.7%
H
25.9
413
|
L
H
25.9
1666
|
L
H
25.9
1666
|
| GT Biopharma Inc |
|
6.6
|
0.6
|
L
 -1.6%
H
0.6
0.7
|
L
 -8.8%
H
0.6
0.7
|
L
 -3.1%
H
0.6
1.4
|
L
 -65.8%
H
0.6
1.9
|
L
 -79.1%
H
0.6
4.1
|
L
 -67.0%
H
0.2
10.7
|
L
 -81.0%
H
0.2
19.7
|
L
 -100.0%
H
0.2
30600
|
| Galapagos NV ADR |
|
2,041.5
|
31.0
|
L
 -2.5%
H
30.8
31.8
|
L
 -3.1%
H
30.8
32.1
|
L
 -13.7%
H
30.8
37.8
|
L
 -5.3%
H
30.8
37.8
|
L
 15.2%
H
22.4
37.8
|
L
 -32.5%
H
22.4
48.1
|
L
 -73.0%
H
22.4
129.0
|
L
 -35.9%
H
22.4
274.0
|
| Genmab ADR |
|
17,672.3
|
28.7
|
L
 0.4%
H
28.5
29.2
|
L
 -4.0%
H
28.3
29.6
|
L
 -10.6%
H
28.3
33.7
|
L
 31.8%
H
21
33.7
|
L
 27.3%
H
17.2
33.7
|
L
 -26.0%
H
17.2
47.5
|
L
 -15.5%
H
17.2
49.1
|
L
 184.5%
H
9.2
49.1
|
| Genfit ADR |
|
193.5
|
3.9
|
L
 0.3%
H
3.8
4.1
|
L
 -10%
H
3.6
4.4
|
L
 -2.8%
H
3.6
4.5
|
L
 1.8%
H
3.4
4.6
|
L
 -34.2%
H
2.6
6.0
|
L
 -4.0%
H
2.6
6.4
|
L
 -2.3%
H
2.6
7.2
|
L
H
2.6
26.3
|
| Genenta Science SpA ADR |
|
60.0
|
2.6
|
L
 -0.4%
H
2.6
2.8
|
L
 -58.7%
H
2.3
4.1
|
L
 -22.7%
H
2.3
10
|
L
 -33.0%
H
2.3
10
|
L
 -53.0%
H
2.3
10
|
L
 -41.1%
H
2.2
10
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
| Grifols SA ADR Level III |
|
6,417.2
|
9.4
|
L
 0.6%
H
9.2
9.6
|
L
 -0.3%
H
9.1
9.6
|
L
 -5.9%
H
9.1
10.2
|
L
 -12.5%
H
9.1
10.9
|
L
 6.7%
H
6.2
11.1
|
L
 45.3%
H
5.3
12.2
|
L
 -45.2%
H
5.3
20.5
|
L
 -46.4%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
7,743.1
|
66.2
|
L
 1.6%
H
64.7
66.4
|
L
 0.1%
H
63.8
67.0
|
L
 -7.7%
H
63.8
71.8
|
L
 12.2%
H
58.7
79.5
|
L
 15.8%
H
42.7
79.5
|
L
 39.7%
H
29.9
79.5
|
L
 133.1%
H
29.9
79.5
|
L
 296.9%
H
7.0
79.5
|
| HCW Biologics Inc |
|
7.7
|
3.6
|
L
 -7.0%
H
3.6
3.8
|
L
 -8.2%
H
3.6
3.9
|
L
 -3.5%
H
3.6
4.9
|
L
 -12.6%
H
2.8
7.4
|
L
 -79.1%
H
0.2
100.8
|
L
 -95.9%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
37.6
|
3.2
|
L
 8.5%
H
3.0
6.9
|
L
 3.6%
H
2.9
6.9
|
L
 4.9%
H
2.7
6.9
|
L
 158.1%
H
1.1
9.1
|
L
 140.6%
H
1.1
9.1
|
L
 -76.3%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
18.6
|
1.4
|
L
 -1.4%
H
1.4
1.4
|
L
 2.2%
H
1.3
1.5
|
L
 -10.3%
H
1.3
1.8
|
L
 7.7%
H
1.1
2.1
|
L
 62.8%
H
0.7
3.8
|
L
 -72.8%
H
0.6
12.5
|
L
 -96.6%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
59.9
|
1.3
|
L
H
1.2
1.3
|
L
 -26.0%
H
1.1
1.8
|
L
 -31.8%
H
1.1
2.2
|
L
 12.9%
H
1.1
2.4
|
L
 -47.2%
H
0.6
2.5
|
L
 -53.9%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
| Harmony Biosciences Holdings |
|
1,687.4
|
29.3
|
L
 2.7%
H
28.4
29.6
|
L
 -3.0%
H
28.4
31.0
|
L
 9.6%
H
25.5
31.0
|
L
 -14.7%
H
25.5
38.3
|
L
 -12.8%
H
25.5
40.9
|
L
 -49.9%
H
18.6
62.1
|
L
 -23.9%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,330.6
|
36.0
|
L
 -4.8%
H
35.8
37.8
|
L
 -6.7%
H
35.8
39.3
|
L
 -24.7%
H
35.8
47.5
|
L
 15.2%
H
29.8
50.7
|
L
 -21.2%
H
20.9
54.2
|
L
 192.1%
H
7.6
59.2
|
L
 653.9%
H
4.8
59.2
|
L
 381.4%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
216.3
|
1.2
|
L
 1.7%
H
1.1
1.3
|
L
 -1.7%
H
1.1
1.3
|
L
 -9.2%
H
1.1
1.4
|
L
 -30.2%
H
1.1
1.9
|
L
 -33.7%
H
1.0
2.7
|
L
 -68.3%
H
0.5
3.9
|
L
 -92.8%
H
0.5
22.4
|
L
 -96.0%
H
0.5
42.9
|
| Quantum BioPharma Ordinary |
|
40.1
|
10.5
|
L
 -5.0%
H
9.3
10.7
|
L
 51.4%
H
9.3
14.9
|
L
 -41.9%
H
9.3
19
|
L
 -55.6%
H
9.3
31.9
|
L
 129.2%
H
2.7
38.3
|
L
 -79.9%
H
2.7
136.5
|
L
 -88.3%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
297.8
|
1.6
|
L
 -4.8%
H
1.6
1.7
|
L
 -7.0%
H
1.6
1.8
|
L
 -11.2%
H
1.6
2.6
|
L
 -30.3%
H
1.4
2.8
|
L
 -70.5%
H
1.2
6.8
|
L
 -54.2%
H
1.2
10.0
|
L
H
1.2
17.5
|
L
H
1.2
17.5
|
| HUTCHMED China ADR |
|
2,631.3
|
15.3
|
L
 4.3%
H
14.7
15.5
|
L
 3.7%
H
14.4
15.5
|
L
 -5.0%
H
14.4
16.4
|
L
 -11.4%
H
14.4
18.3
|
L
 -17.8%
H
11.5
19.5
|
L
 76.8%
H
8.4
21.9
|
L
 -49.2%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
2,226.0
|
2.3
|
L
 -5.8%
H
2.3
2.4
|
L
 -8.5%
H
2.3
2.7
|
L
 -9.6%
H
2.3
2.8
|
L
 -4.6%
H
2.2
3.0
|
L
 -57.2%
H
1.8
5.9
|
L
 -57.9%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Immucell Corp |
|
56.2
|
6.2
|
L
 -0.5%
H
5.9
6.2
|
L
 2.1%
H
5.9
6.8
|
L
 -5.2%
H
5.9
7.0
|
L
 3.5%
H
5.6
7.0
|
L
 73.5%
H
3.4
7.6
|
L
 -22.9%
H
3.3
8.6
|
L
 19.2%
H
3.3
13.2
|
L
 -8.7%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,748.5
|
31.4
|
L
 -1.6%
H
30.6
32.0
|
L
 7.5%
H
29.1
33.6
|
L
 15.3%
H
26.1
33.6
|
L
 29.2%
H
22.1
33.6
|
L
 12.7%
H
13.5
33.6
|
L
 85.2%
H
13.3
47.7
|
L
 152.1%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx NV |
|
93.5
|
1.4
|
L
 -5.5%
H
1.3
1.5
|
L
 -1.4%
H
1.3
1.7
|
L
H
1.1
1.7
|
L
 60.5%
H
0.7
1.8
|
L
 -12.7%
H
0.7
2.8
|
L
 -47.5%
H
0.7
7.3
|
L
 -65.6%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
93.9
|
8.4
|
L
 -3.6%
H
8.1
8.8
|
L
 5%
H
8.1
9.1
|
L
 -2.8%
H
7.2
9.1
|
L
 -51.4%
H
7.2
17.5
|
L
 -59.3%
H
7.2
23.3
|
L
 -73.1%
H
7.2
91.7
|
L
H
7.2
451.3
|
L
H
7.2
451.3
|
| Inhibikase Therapeutics Inc |
|
119.2
|
1.6
|
L
 8.8%
H
1.3
1.8
|
L
 3.9%
H
1.3
1.8
|
L
 -2.4%
H
1.3
1.8
|
L
 5.3%
H
1.3
1.9
|
L
 -38.9%
H
1.3
4.2
|
L
 -66.0%
H
0.8
6.9
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
| Illumina Inc |
|
18,442.5
|
120.0
|
L
 -2.9%
H
116.3
124.1
|
L
 19.9%
H
94
124.1
|
L
 20.8%
H
88
124.1
|
L
 26.8%
H
88
124.1
|
L
 -19.9%
H
68.7
156.7
|
L
 -43.1%
H
68.7
248.9
|
L
 -59.0%
H
68.7
555.8
|
L
 -19.4%
H
68.7
555.8
|
| IM Cannabis Corp |
|
7.3
|
1.4
|
L
 -3.5%
H
1.4
1.5
|
L
 -6.7%
H
1.3
1.6
|
L
 -27.6%
H
1.3
2.6
|
L
 -45.1%
H
1.3
3.1
|
L
 -32.5%
H
1.3
7.1
|
L
 -94.8%
H
0.4
27
|
L
 -99.6%
H
0.4
697.8
|
L
H
0.4
697.8
|
| Immix Biopharma Inc |
|
120.2
|
3.6
|
L
 -4.2%
H
3.4
3.9
|
L
 0.8%
H
3.3
4.1
|
L
 73.3%
H
2
4.1
|
L
 37.4%
H
1.9
4.1
|
L
 128.9%
H
1.3
4.1
|
L
 260.4%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immunome Inc |
|
1,479.8
|
17
|
L
 5.8%
H
15.8
17.9
|
L
 8.4%
H
15.4
17.9
|
L
 48.2%
H
11.6
17.9
|
L
 60.5%
H
8.7
17.9
|
L
 45.3%
H
5.2
17.9
|
L
 318.7%
H
2.2
31.0
|
L
 54.8%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
11.1
|
4.4
|
L
 -3.5%
H
4.3
4.6
|
L
 -9.5%
H
4.3
4.9
|
L
 -19.3%
H
4.3
5.6
|
L
 -48.4%
H
4.3
9.4
|
L
 -68.6%
H
4.3
47.4
|
L
 -80.4%
H
4.3
54.8
|
L
 -95.9%
H
4.3
783
|
L
 -99.9%
H
4.3
7276.5
|
| Immuneering Corp Ordinary |
|
414.8
|
6.6
|
L
 -4.5%
H
6.5
7.2
|
L
 8.6%
H
5.9
7.2
|
L
 0.5%
H
5.2
7.2
|
L
 94.7%
H
2.9
10.1
|
L
 250.8%
H
1.1
10.1
|
L
 -50.0%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics NV |
|
1,176.7
|
9.7
|
L
 -5%
H
9.5
10.3
|
L
 -4.9%
H
9.5
10.9
|
L
 10.9%
H
8.6
11.3
|
L
 49.4%
H
5.1
11.3
|
L
 4.1%
H
3.3
11.3
|
L
 -9.0%
H
3.3
13.8
|
L
 -3.7%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunic Inc |
|
74.0
|
0.8
|
L
 -3.9%
H
0.7
0.8
|
L
 -2.6%
H
0.7
0.9
|
L
 -21.9%
H
0.7
1
|
L
 -19.4%
H
0.7
1.1
|
L
 -38.5%
H
0.6
1.4
|
L
 -56.1%
H
0.6
3.2
|
L
 -94.9%
H
0.6
28.2
|
L
 -99.8%
H
0.6
472
|
| Immunovant Inc |
|
4,145.3
|
23.8
|
L
 -3.7%
H
23.7
25.2
|
L
 25.6%
H
19.2
26.2
|
L
 42.1%
H
16.0
26.2
|
L
 51.4%
H
14.3
26.2
|
L
 -19.1%
H
12.7
32.1
|
L
 113.7%
H
10.7
45.6
|
L
 -46.7%
H
3.1
53.8
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
8.5
|
1.9
|
L
 -3.6%
H
1.8
2.0
|
L
 -12.2%
H
1.8
2.2
|
L
 -17.9%
H
1.8
2.7
|
L
 -10.9%
H
1.8
2.7
|
L
 526.7%
H
0.1
4.2
|
L
 -6%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,858.5
|
81.4
|
L
 -0.3%
H
77.6
82.5
|
L
 42.2%
H
53.4
84.0
|
L
 132.3%
H
28.2
84.0
|
L
 277.0%
H
20.6
84.0
|
L
 415.4%
H
10.8
84.0
|
L
 154.2%
H
10.8
84.0
|
L
 410.3%
H
7.7
84.0
|
L
H
7.7
84.0
|
| Incyte |
|
19,940.5
|
101.6
|
L
 8.7%
H
91.2
101.8
|
L
 11.3%
H
84.0
101.8
|
L
 17.7%
H
82.8
101.8
|
L
 34.4%
H
75.5
101.8
|
L
 33.4%
H
53.6
101.8
|
L
 31.7%
H
50.3
101.8
|
L
 20.3%
H
50.3
101.8
|
L
 -15.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
3.5
|
3.1
|
L
 -3.1%
H
2.9
3.3
|
L
 -14.1%
H
2.9
3.8
|
L
 -13.1%
H
2.9
5.3
|
L
 -57.3%
H
2.2
8.7
|
L
 169.0%
H
0.3
13.4
|
L
 63.4%
H
0.3
13.4
|
L
 -68.0%
H
0.3
36.8
|
L
 -99.3%
H
0.3
8800
|
| Indivior Plc |
|
3,895.4
|
31.2
|
L
 6.2%
H
29.6
31.6
|
L
 24.2%
H
24.3
31.6
|
L
 34.1%
H
22.6
31.6
|
L
 48.2%
H
20.7
31.6
|
L
 235.8%
H
7.6
31.6
|
L
 57.1%
H
3.1
31.6
|
L
 2128.6%
H
1.2
31.6
|
L
 872.0%
H
0.4
31.6
|
| MiNK Therapeutics Inc |
|
60.8
|
13.5
|
L
 -4.2%
H
13.4
14.3
|
L
 -10.2%
H
13.4
14.9
|
L
 -13%
H
13.4
16
|
L
 -8.6%
H
11.6
18.2
|
L
 89.7%
H
0.9
76
|
L
 -36.9%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharmaceuticals Inc |
|
4.4
|
1.9
|
L
 -1.6%
H
1.8
1.9
|
L
 -10.6%
H
1.8
2.1
|
L
 -18.1%
H
1.8
2.5
|
L
 -22.6%
H
1.8
2.5
|
L
 -64.6%
H
1.7
8.3
|
L
 -96.9%
H
1.7
95
|
L
 -99.9%
H
1.7
4470
|
L
 -99.9%
H
1.7
32175
|
| INmune Bio Inc |
|
47.9
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -5.3%
H
1.7
2.0
|
L
 -15.9%
H
1.7
2.2
|
L
 -29.7%
H
1.7
3.0
|
L
 -70.2%
H
1.7
11.6
|
L
 -75.1%
H
1.7
14.7
|
L
 -76.0%
H
1.7
30.4
|
L
H
1.7
30.4
|
| Inovio Pharmaceuticals Inc |
|
132.9
|
2.5
|
L
 6.4%
H
2.3
2.5
|
L
 7.3%
H
2.3
2.7
|
L
 1.6%
H
2.2
2.7
|
L
 74.8%
H
1.4
3.0
|
L
 -54.1%
H
1.3
5.8
|
L
 17.4%
H
0.3
14.8
|
L
 -75.0%
H
0.3
19
|
L
 -62.5%
H
0.3
33.8
|
| Insmed Inc |
|
39,717.9
|
186.2
|
L
 -1.8%
H
178.8
188.6
|
L
 16.6%
H
160.5
197.1
|
L
 21.9%
H
151.8
197.1
|
L
 71.3%
H
106.5
197.1
|
L
 172.6%
H
60.4
197.1
|
L
 958.7%
H
16.0
197.1
|
L
 492.1%
H
16.0
197.1
|
L
 831.6%
H
9.0
197.1
|
| Innoviva Inc |
|
1,141.3
|
18.1
|
L
 -0.5%
H
17.8
18.3
|
L
 2.3%
H
17.5
18.3
|
L
 2.6%
H
16.5
18.8
|
L
 -2.8%
H
16.5
21.1
|
L
 -6.0%
H
16.5
22
|
L
 37.7%
H
10.6
22
|
L
 76.7%
H
10.1
22
|
L
 103.5%
H
7.6
22
|
| IO Biotech Inc |
|
60.0
|
0.9
|
L
 -12.5%
H
0.9
1.0
|
L
 -9%
H
0.8
1.1
|
L
 106.8%
H
0.4
1.2
|
L
 -59.0%
H
0.3
2.8
|
L
 -27.8%
H
0.3
2.8
|
L
 -62.9%
H
0.3
3.5
|
L
H
0.3
17.9
|
L
H
0.3
17.9
|
| Ionis Pharmaceuticals Inc |
|
11,929.4
|
73.7
|
L
 -0.9%
H
72.0
75.3
|
L
 3.9%
H
71.1
75.5
|
L
 7.7%
H
67.6
75.5
|
L
 71.2%
H
40.0
75.5
|
L
 90.0%
H
24.0
75.5
|
L
 64.8%
H
24.0
75.5
|
L
 57.5%
H
24.0
75.5
|
L
 41.8%
H
19.6
86.6
|
| Iovance Biotherapeutics Inc |
|
705.6
|
2.0
|
L
 -1.0%
H
1.9
2.2
|
L
 -13.3%
H
1.9
2.4
|
L
 -13.3%
H
1.9
2.4
|
L
 -27.2%
H
1.9
2.9
|
L
 -82.6%
H
1.6
12.5
|
L
 -78.1%
H
1.6
18.3
|
L
 -94.6%
H
1.6
54.2
|
L
 -70.9%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
51.8
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 20%
H
0.5
0.6
|
L
 13.2%
H
0.5
0.6
|
L
 -52.4%
H
0.3
1.8
|
L
 -94.2%
H
0.3
12.0
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
3,166.1
|
84.7
|
L
 -1.8%
H
83.4
87.5
|
L
 -1.1%
H
83.4
89.8
|
L
 28.6%
H
65.4
96.0
|
L
 43.6%
H
56.4
96.0
|
L
 79.7%
H
30.8
96.0
|
L
 389.5%
H
11.8
96.0
|
L
 -15.4%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Ironwood Pharmaceuticals Inc |
|
302.1
|
1.9
|
L
 -3.1%
H
1.8
2.1
|
L
 12.1%
H
1.5
2.1
|
L
 15.5%
H
1.4
2.1
|
L
 141.6%
H
0.7
2.1
|
L
 -55.6%
H
0.5
5.1
|
L
 -83.0%
H
0.5
15.7
|
L
 -80.9%
H
0.5
15.7
|
L
 -80.6%
H
0.5
17.7
|
| Iterum Therapeutics Plc |
|
31.2
|
0.7
|
L
 -3.0%
H
0.7
0.7
|
L
 -7.1%
H
0.6
0.7
|
L
 -3.0%
H
0.6
0.8
|
L
 -11.0%
H
0.6
0.9
|
L
 -46.7%
H
0.6
3.0
|
L
 -60.8%
H
0.6
3.0
|
L
 -90.6%
H
0.6
44.9
|
L
H
0.6
195
|
| Invivyd Inc |
|
345.2
|
1.6
|
L
 -8.5%
H
1.6
1.9
|
L
 -27.8%
H
1.6
2.3
|
L
 32.0%
H
1.1
2.4
|
L
 120.6%
H
0.5
2.4
|
L
 76.9%
H
0.4
2.7
|
L
 -55.9%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| IMab ADR |
|
541.8
|
4.7
|
L
 -5.1%
H
4.7
5.1
|
L
 11.4%
H
4.4
5.1
|
L
 13.8%
H
4.0
6.8
|
L
 79.4%
H
2.8
6.8
|
L
 339.3%
H
0.6
6.8
|
L
 28.8%
H
0.6
7.7
|
L
 -88.2%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings plc ADR |
|
1,631.5
|
32.4
|
L
 -2.2%
H
31.4
34.5
|
L
 -2.2%
H
31.4
34.5
|
L
 -8.3%
H
31.4
35.5
|
L
 -1.9%
H
31.0
38.2
|
L
 2.2%
H
23.2
39.3
|
L
 -42.6%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep ADR |
|
269.4
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
 -10.3%
H
1.8
2.1
|
L
 -2.7%
H
1.8
2.3
|
L
 6.4%
H
1.6
2.3
|
L
 0.6%
H
1.3
2.7
|
L
 1.7%
H
1.3
3.9
|
L
 5.8%
H
1.3
8.0
|
L
 -53.4%
H
0.5
8.0
|
| Immuron ADR |
|
13.5
|
2
|
L
 5.3%
H
1.9
2
|
L
 -7.0%
H
1.8
2.2
|
L
 -2.9%
H
1.8
2.4
|
L
 21.2%
H
1.6
2.4
|
L
 2.6%
H
1.5
2.5
|
L
 -2.0%
H
1.4
6.0
|
L
 -66.7%
H
1.4
9.5
|
L
H
1.4
29.0
|
| Innate Pharma ADR |
|
175.1
|
1.9
|
L
 -3.6%
H
1.8
2.0
|
L
 -13.6%
H
1.8
2.4
|
L
 -5.5%
H
1.8
2.4
|
L
 -11.6%
H
1.8
2.4
|
L
 1.1%
H
1.3
3.5
|
L
 -7.3%
H
1.3
4.0
|
L
 -54.0%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Inventiva ADR |
|
598.0
|
4.1
|
L
 -4.7%
H
3.9
4.3
|
L
 -33.9%
H
3.8
8.0
|
L
 -34.9%
H
3.8
8.0
|
L
 27.3%
H
3.2
8.0
|
L
 49.6%
H
2.1
8.0
|
L
 -9.5%
H
1.5
8.0
|
L
 -68.1%
H
1.5
19.1
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
6.9
|
1.9
|
L
 -4.6%
H
1.8
2
|
L
 -11.9%
H
1.8
2.1
|
L
 -16.3%
H
1.8
2.4
|
L
 -6.6%
H
1.6
2.7
|
L
 74.5%
H
0.4
15.5
|
L
 -99.7%
H
0.4
720
|
L
 -99.9%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
| Janux Therapeutics Inc |
|
1,644.8
|
27.4
|
L
 -4.7%
H
27
29.2
|
L
 9.9%
H
25.3
31.6
|
L
 17.4%
H
22.2
31.6
|
L
 16.2%
H
21.7
31.6
|
L
 -49.7%
H
21.7
71.7
|
L
 50.2%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharmaceuticals plc |
|
8,394.0
|
138.4
|
L
 0.5%
H
136.7
138.5
|
L
 -0.1%
H
133.5
140
|
L
 0.9%
H
132.4
140.4
|
L
 19.8%
H
105
140.4
|
L
 25.3%
H
95.5
148.1
|
L
 -3.4%
H
95.5
161.0
|
L
 -6.0%
H
95.5
189
|
L
 -3.1%
H
86.9
189
|
| Jasper Therapeutics Inc |
|
58.6
|
2.1
|
L
 -7.9%
H
2.1
2.3
|
L
 -11.4%
H
2.1
2.5
|
L
 -13.2%
H
2.1
2.7
|
L
 -27.1%
H
2.1
3.1
|
L
 -90.1%
H
2.1
26.1
|
L
 187.7%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharmaceuticals Inc |
|
5.3
|
0.8
|
L
 -2.6%
H
0.8
0.8
|
L
 -5%
H
0.7
0.8
|
L
 -50.7%
H
0.7
1.7
|
L
 -89.9%
H
0.7
20.6
|
L
 -89.1%
H
0.7
20.6
|
L
 -86.7%
H
0.7
56.7
|
L
 -99.8%
H
0.7
498.5
|
L
H
0.7
1337.5
|
| KalVista Pharmaceuticals Inc |
|
545.7
|
10.8
|
L
 -1.0%
H
10.5
11.2
|
L
 -3.0%
H
10.5
11.5
|
L
 -8.1%
H
10.5
12.2
|
L
 -18.2%
H
10.5
17.3
|
L
 1.8%
H
7.3
17.3
|
L
 103.8%
H
5.0
17.3
|
L
 -35.9%
H
4.1
45
|
L
 -80.8%
H
4.1
67.5
|
| Kamada |
|
396.2
|
6.9
|
L
 -0.4%
H
6.8
7.0
|
L
 0.3%
H
6.8
7.1
|
L
 1.3%
H
6.5
7.2
|
L
 -4.6%
H
6.5
7.9
|
L
 16.4%
H
5.5
9.2
|
L
 47.2%
H
3.7
9.2
|
L
 -6.6%
H
3.7
9.2
|
L
 74.9%
H
3.3
13.3
|
| Kiniksa Pharmaceuticals |
|
2,840.1
|
37.5
|
L
 1.2%
H
36.6
37.9
|
L
 -3.8%
H
35.2
42.1
|
L
H
35.2
42.1
|
L
 17.2%
H
31.8
42.1
|
L
 66.7%
H
17.8
42.1
|
L
 202.2%
H
10.3
42.1
|
L
 143.0%
H
7.4
42.1
|
L
H
5.0
42.1
|
| Kodiak Sciences Inc |
|
980.4
|
18.6
|
L
 2.4%
H
17.0
18.7
|
L
 -0.7%
H
17.0
21.2
|
L
 38.2%
H
10.9
21.2
|
L
 179.1%
H
6.4
21.2
|
L
 383.3%
H
1.9
21.2
|
L
 167.8%
H
1.4
21.2
|
L
 -79.6%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Kiora Pharmaceuticals Inc |
|
8.5
|
2.5
|
L
 6.9%
H
2.2
2.5
|
L
 -3.5%
H
2.2
2.7
|
L
 -12.1%
H
2.2
3.0
|
L
 -2.8%
H
2.2
3.0
|
L
 -31.4%
H
2.2
4.2
|
L
 -60.1%
H
0.4
8.5
|
L
 -98.2%
H
0.4
327.2
|
L
 -99.8%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
96.7
|
6.1
|
L
 4.7%
H
5.7
6.2
|
L
 -4.3%
H
5.7
6.6
|
L
 -3.5%
H
4.5
6.8
|
L
 54.5%
H
3.7
8.2
|
L
 -55.2%
H
0.6
14.2
|
L
 -91.5%
H
0.6
89.6
|
L
 -97.2%
H
0.6
270
|
L
 -97.1%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
463.7
|
15.2
|
L
H
14.9
15.2
|
L
 1.2%
H
14.8
15.5
|
L
 -2.3%
H
13.6
16.6
|
L
 6.3%
H
13.1
16.6
|
L
 -74.3%
H
9.1
72.4
|
L
 -69.3%
H
9.1
73
|
L
 -70.6%
H
9.1
88.8
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
5,726.4
|
197.9
|
L
 0.2%
H
184.0
199.0
|
L
 6.3%
H
183.3
199.0
|
L
 8.9%
H
179.2
199.0
|
L
 26.0%
H
130.5
199.0
|
L
 12.2%
H
122.8
207.8
|
L
 167.4%
H
69.8
219.3
|
L
 359.7%
H
38.9
219.3
|
L
H
8.0
219.3
|
| TuHURA Biosciences Inc |
|
129.8
|
2.5
|
L
 -0.4%
H
2.5
2.6
|
L
 10.9%
H
2.3
2.6
|
L
 -2.7%
H
2.2
2.7
|
L
 5.8%
H
2.2
3.9
|
L
 -55.4%
H
1.8
7.2
|
L
 -98.6%
H
0.2
542.5
|
L
 -99.9%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
6.1
|
0.8
|
L
 1.2%
H
0.8
0.8
|
L
 13.9%
H
0.7
0.8
|
L
 3.8%
H
0.7
0.8
|
L
 17.1%
H
0.7
0.9
|
L
 -78.4%
H
0.7
4.4
|
L
 -23.4%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
848.0
|
9.8
|
L
 -4.9%
H
8.9
10.4
|
L
 0.7%
H
8.9
11.1
|
L
 6.9%
H
8.9
11.1
|
L
 62.3%
H
5.5
11.1
|
L
 -42.1%
H
5.4
19.7
|
L
 -37.3%
H
5.4
24.2
|
L
 -68.9%
H
5.4
43
|
L
 -51.2%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
4,269.8
|
59.7
|
L
 -3.4%
H
57.5
63.4
|
L
 2.0%
H
57.5
63.4
|
L
 6.6%
H
55.3
64.0
|
L
 39.0%
H
36.7
64.0
|
L
 31.1%
H
19.4
64.0
|
L
 107.7%
H
9.6
64.0
|
L
 65.1%
H
9.6
91.9
|
L
H
9.6
91.9
|
| Kezar Life Sciences Inc |
|
44.9
|
6.1
|
L
 -1.3%
H
6.1
6.2
|
L
 -0.5%
H
6.1
6.3
|
L
 57.6%
H
3.5
6.4
|
L
 51.4%
H
3.5
6.4
|
L
 -15.0%
H
3.5
7.7
|
L
 -91.7%
H
0.7
82.5
|
L
 -87.4%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics ADR |
|
12.9
|
7.8
|
L
 -0.8%
H
7.5
7.8
|
L
 11.0%
H
6.5
8.0
|
L
 22.8%
H
6.2
8.0
|
L
 -5.3%
H
6.2
9.0
|
L
 -71.9%
H
2.9
39.1
|
L
 -79.1%
H
2.9
84
|
L
 -97.3%
H
2.9
792.5
|
L
 -98.5%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
23.1
|
1.0
|
L
 2.0%
H
1.0
1.1
|
L
 11.8%
H
0.9
1.1
|
L
 16.9%
H
0.8
1.1
|
L
 22.4%
H
0.8
1.6
|
L
 -54.6%
H
0.8
2.9
|
L
 -52.1%
H
0.7
6.9
|
L
 -81.8%
H
0.7
12.5
|
L
 -80.5%
H
0.7
76.2
|
| Lifecore Biomedical Inc |
|
266.4
|
7.1
|
L
 -1.1%
H
7.0
7.2
|
L
 4.9%
H
6.6
7.4
|
L
 0.7%
H
6.3
7.5
|
L
 1.7%
H
6.3
8.7
|
L
 20.9%
H
4.8
8.9
|
L
 -22.4%
H
1.5
11.5
|
L
 -26.2%
H
1.5
12.9
|
L
 -42.8%
H
1.5
15.6
|
| Lifevantage Corporation |
|
93.2
|
7.3
|
L
 -10.4%
H
7.1
8.2
|
L
 -15.3%
H
7.1
8.9
|
L
 -23.3%
H
7.1
9.8
|
L
 -41.7%
H
7.1
15
|
L
 -43.5%
H
7.1
27.4
|
L
 94.2%
H
3.0
27.4
|
L
 -35.0%
H
3.0
27.4
|
L
 -3.3%
H
2.9
27.4
|
| Ligand Pharmaceuticals Inc |
|
3,728.1
|
191.2
|
L
 0.0%
H
183.9
193.0
|
L
 2.3%
H
182.9
194.4
|
L
 6.2%
H
177.4
194.4
|
L
 44.1%
H
131.7
194.4
|
L
 73.8%
H
93.6
194.4
|
L
 181.2%
H
49.3
194.4
|
L
 257.5%
H
46.8
194.4
|
L
 211.7%
H
36.9
194.4
|
| Longeveron Inc Ordinary |
|
17.5
|
0.8
|
L
H
0.8
0.9
|
L
 -9.8%
H
0.8
0.9
|
L
 9.2%
H
0.8
1.0
|
L
 -49.4%
H
0.6
1.8
|
L
 -60.5%
H
0.6
2.3
|
L
 -97.7%
H
0.6
45.8
|
L
H
0.6
450
|
L
H
0.6
450
|
| Atyr Pharma Inc |
|
86.2
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -9.3%
H
0.8
1.0
|
L
 23.9%
H
0.7
1.1
|
L
 -81.3%
H
0.7
6.5
|
L
 -71.1%
H
0.7
7.3
|
L
 -63.8%
H
0.7
7.3
|
L
 -71.3%
H
0.7
13.1
|
L
 -99.5%
H
0.7
185.6
|
| Lixte Biotechnology Holdings |
|
25.3
|
4.4
|
L
 3.3%
H
4.2
4.5
|
L
 2.3%
H
4.1
4.6
|
L
 -17.5%
H
3.9
5.5
|
L
 -9.0%
H
3.1
6.3
|
L
 119.3%
H
0.6
6.3
|
L
 -14.8%
H
0.6
27
|
L
 -92.6%
H
0.6
71.9
|
L
 -56.6%
H
0.6
110.4
|
| Lipocine Inc |
|
14.4
|
2.7
|
L
 -0.4%
H
2.6
2.7
|
L
 -8.6%
H
2.6
2.9
|
L
 -14.2%
H
2.6
3.5
|
L
 -15.9%
H
2.6
3.5
|
L
 -56.4%
H
2.6
6.2
|
L
 -61.3%
H
2.3
11.8
|
L
 -87.0%
H
2.3
41.1
|
L
 -98.7%
H
2.3
251.5
|
| Leap Therapeutics Inc |
|
23.8
|
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 -12.5%
H
0.4
0.6
|
L
 -42.5%
H
0.4
1.0
|
L
 35.5%
H
0.2
1.0
|
L
 -88.8%
H
0.2
3.9
|
L
 -94.8%
H
0.2
10.2
|
L
 -97.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
2,171.2
|
25.2
|
L
 3.5%
H
22.2
27.2
|
L
 12.7%
H
22.1
27.2
|
L
 15.2%
H
21.9
27.2
|
L
 42.7%
H
17.8
29.9
|
L
 129.7%
H
9.7
29.9
|
L
 405.4%
H
4.5
29.9
|
L
 655.1%
H
2.3
29.9
|
L
H
2.3
38.5
|
| Larimar Therapeutics Inc |
|
332.1
|
3.9
|
L
 -0.3%
H
3.8
4.1
|
L
 -7.8%
H
3.8
4.5
|
L
 -9.4%
H
3.8
5
|
L
 12.8%
H
3.1
5.4
|
L
 -51.9%
H
1.6
9.5
|
L
 25.6%
H
1.6
13.7
|
L
 -80.1%
H
1.5
25.9
|
L
 -96.8%
H
1.5
219
|
| Lisata Therapeutics Inc |
|
23.4
|
2.7
|
L
 -4.3%
H
2.6
2.8
|
L
 13.6%
H
2.3
3.0
|
L
 4.7%
H
2.3
3.0
|
L
 7.2%
H
2.1
3.1
|
L
 -15.5%
H
1.9
4.2
|
L
 -36.9%
H
1.9
4.5
|
L
 -88.3%
H
1.9
73.4
|
L
 -98.7%
H
1.9
225
|
| Lantern Pharma Inc |
|
41.3
|
3.8
|
L
 -4.7%
H
3.8
4
|
L
 -6.4%
H
3.8
4.3
|
L
 -5.0%
H
3.7
4.7
|
L
 -19.9%
H
3.7
5.7
|
L
 17.5%
H
2.6
6.1
|
L
 -10.3%
H
2.4
12.0
|
L
 -74.9%
H
2.4
23.5
|
L
H
2.4
24.8
|
| LAVA Therapeutics NV |
|
42.9
|
1.6
|
L
 0.6%
H
1.6
1.6
|
L
 1.2%
H
1.6
1.6
|
L
 5.2%
H
1.4
1.6
|
L
 14.8%
H
1.4
1.6
|
L
 -14.2%
H
0.9
2
|
L
 -64.4%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
| Lexicon Pharmaceuticals Inc |
|
494.2
|
1.4
|
L
 -1.5%
H
1.4
1.4
|
L
 -4.2%
H
1.3
1.5
|
L
 -1.5%
H
1.3
1.7
|
L
 27.1%
H
1.0
1.7
|
L
 11.5%
H
0.3
1.7
|
L
 -35.5%
H
0.3
3.8
|
L
 29.5%
H
0.3
9.7
|
L
 -86.7%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
317.9
|
16.6
|
L
 -0.7%
H
15.9
17.3
|
L
 -6.2%
H
15.9
17.7
|
L
 4.7%
H
15.7
19.5
|
L
 50.2%
H
9.3
19.5
|
L
 -26.1%
H
7.7
30
|
L
 -85.0%
H
7.7
119.3
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Lyra Therapeutics Inc |
|
9.5
|
5.8
|
L
 -0.2%
H
5.7
6.5
|
L
 -9.7%
H
5.5
6.5
|
L
 -17.9%
H
5.5
8.8
|
L
 -12.6%
H
5.5
8.8
|
L
 -57.9%
H
3.8
37.5
|
L
 -97.6%
H
3.8
339.5
|
L
 -98.9%
H
3.8
825
|
L
H
3.8
1100
|
| Legend Biotech Corp ADR |
|
5,930.3
|
32.1
|
L
 -0.8%
H
31.8
32.8
|
L
 0.9%
H
31.4
33.4
|
L
 -0.5%
H
30.8
34.8
|
L
 -17.2%
H
30.8
39.2
|
L
 -27.8%
H
27.3
47.8
|
L
 -36.4%
H
27.3
77.3
|
L
 23.8%
H
23.4
77.3
|
L
H
23.4
77.3
|
| Mustang Bio Inc |
|
10.1
|
1.4
|
L
 -4.1%
H
1.4
1.5
|
L
 -6.7%
H
1.4
1.5
|
L
 -12.0%
H
1.4
1.9
|
L
 -5.4%
H
1.3
1.9
|
L
 -89.6%
H
0.1
21.9
|
L
 -99.7%
H
0.1
554.2
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
142.4
|
2.1
|
L
 -4.9%
H
2.1
2.3
|
L
 -12.4%
H
2.1
2.5
|
L
 -33.1%
H
2.1
3.5
|
L
 -16.9%
H
2.1
4.7
|
L
 123.2%
H
0.9
4.7
|
L
 -42.2%
H
0.8
4.7
|
L
 -69.9%
H
0.8
10.7
|
L
 -99.7%
H
0.8
1020.6
|
| Moleculin Biotech Inc |
|
25.7
|
0.5
|
L
 13.0%
H
0.4
0.6
|
L
 6.1%
H
0.4
0.6
|
L
 4%
H
0.4
0.6
|
L
 -21.2%
H
0.4
0.7
|
L
 -78.8%
H
0.3
3.7
|
L
 -96.6%
H
0.3
132.8
|
L
 -99.1%
H
0.3
132.8
|
L
H
0.3
862.2
|
| Seres Therapeutics Inc |
|
133.4
|
15.2
|
L
 -5.3%
H
15.1
16.7
|
L
 -14.6%
H
15.1
18.4
|
L
 -27.6%
H
15.1
22
|
L
 8.9%
H
13.5
24.7
|
L
 1758.5%
H
0.4
24.7
|
L
 86.1%
H
0.4
24.7
|
L
 -48.4%
H
0.4
38.5
|
L
 -50.5%
H
0.4
44.5
|
| Madrigal Pharmaceuticals Inc |
|
9,190.9
|
412.4
|
L
 -1.6%
H
399
430.5
|
L
 -2.2%
H
393.6
436.8
|
L
 -8.3%
H
393.6
453.6
|
L
 36.5%
H
299.2
463.6
|
L
 29.0%
H
265
463.6
|
L
 480.0%
H
57.2
463.6
|
L
 223.9%
H
52.3
463.6
|
L
 1632.6%
H
5.3
463.6
|
| MediWound |
|
234.9
|
18.3
|
L
 -0.1%
H
17.9
18.5
|
L
 -0.7%
H
17.9
18.8
|
L
 7.3%
H
17.0
20.0
|
L
 -1.1%
H
16.1
20.3
|
L
 -0.3%
H
14.1
22.5
|
L
 85.6%
H
7.1
24
|
L
 -23.0%
H
7.1
43.5
|
L
 -71.9%
H
7.1
73.3
|
| Lite Strategy Inc |
|
68.5
|
1.9
|
L
 -8.1%
H
1.9
2.1
|
L
 -1.0%
H
1.9
2.2
|
L
 -28.4%
H
1.8
3.0
|
L
 -60.6%
H
1.8
5.6
|
L
 -37.5%
H
1.5
9
|
L
 -71.6%
H
1.5
9
|
L
 -96.4%
H
1.5
91.5
|
L
 -94.7%
H
1.5
102.8
|
| Macrogenics Inc |
|
99.9
|
1.6
|
L
 -4.8%
H
1.5
1.7
|
L
 -14.1%
H
1.5
1.9
|
L
 -7.6%
H
1.5
2.2
|
L
H
1.4
2.2
|
L
 -59.2%
H
1.0
5.1
|
L
 -67.4%
H
1.0
21.9
|
L
 -91.9%
H
1.0
36.5
|
L
 -95.3%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
21.3
|
1.9
|
L
 -10.6%
H
1.8
2.1
|
L
 -20.2%
H
1.8
2.4
|
L
 -15.1%
H
1.8
2.8
|
L
 8.8%
H
1.4
2.8
|
L
 -17.7%
H
1.3
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| MeiraGTx Holdings plc |
|
702.3
|
8.7
|
L
 -3.9%
H
8.5
9.2
|
L
 0.1%
H
8.5
9.5
|
L
 3.9%
H
7.5
9.5
|
L
 14.1%
H
7.2
9.5
|
L
 50.3%
H
4.6
9.5
|
L
 23.8%
H
3.5
9.5
|
L
 -34.3%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharmaceuticals Inc |
|
3,559.3
|
70.9
|
L
 -2.5%
H
68.7
73.0
|
L
 1.2%
H
68.3
73.2
|
L
 -1.3%
H
67.0
78.5
|
L
 36.2%
H
50.3
78.5
|
L
 75.4%
H
36.9
78.5
|
L
 204.9%
H
17.5
78.5
|
L
 330.2%
H
12.8
78.5
|
L
H
6.5
78.5
|
| Milestone Pharmaceuticals Inc |
|
157.2
|
1.9
|
L
 -3.7%
H
1.9
2.0
|
L
 -1.6%
H
1.8
2.0
|
L
 -15.1%
H
1.8
2.3
|
L
 29.4%
H
1.4
2.3
|
L
 28.5%
H
0.6
2.6
|
L
 -63.2%
H
0.6
5.2
|
L
 -68.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics |
|
647.7
|
10.2
|
L
 1.0%
H
10.1
10.6
|
L
 7.1%
H
9.4
10.6
|
L
 36.7%
H
7.5
11.0
|
L
 -80.7%
H
6.0
62.8
|
L
 -78%
H
6.0
62.8
|
L
 44.7%
H
6.0
65.0
|
L
 -1.0%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
2,980.8
|
39.2
|
L
 -4.1%
H
38
42
|
L
 -1.8%
H
38
43.4
|
L
 -3.2%
H
35.3
44.8
|
L
 186.8%
H
12.6
44.8
|
L
 191.2%
H
8.2
44.8
|
L
H
5.9
44.8
|
L
H
5.9
44.8
|
L
H
5.9
44.8
|
| Mannkind Corp |
|
1,681.4
|
5.5
|
L
 -2.0%
H
5.5
5.7
|
L
 3.2%
H
5.2
5.7
|
L
 -0.2%
H
4.8
5.9
|
L
 46.1%
H
3.4
6.2
|
L
 -23.6%
H
3.4
7.6
|
L
 61.7%
H
3.2
7.6
|
L
 174%
H
2.0
7.6
|
L
 -65.6%
H
0.7
16.5
|
| Mind Medicine Inc |
|
1,194.8
|
12.3
|
L
 -13.5%
H
12.1
14.2
|
L
 -0.7%
H
12.1
14.4
|
L
 0.6%
H
11.6
14.4
|
L
 45.6%
H
8.6
14.4
|
L
 96.3%
H
4.7
14.4
|
L
 340.5%
H
2.1
14.4
|
L
 2.8%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
73.6
|
1.5
|
L
 -9.6%
H
1.5
1.7
|
L
 22.0%
H
1.2
2.0
|
L
 21.0%
H
1.2
2.0
|
L
 4.9%
H
1.2
2.0
|
L
 -9.6%
H
1.1
2.6
|
L
 -27.9%
H
1.1
2.7
|
L
 -72.7%
H
1.1
10.8
|
L
 -49.3%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
518.3
|
84
|
L
 -2.5%
H
77
86.2
|
L
 3.0%
H
77
89.9
|
L
 -13.6%
H
72
105
|
L
 106.4%
H
29.2
105
|
L
 474.2%
H
13.9
105
|
L
 471.4%
H
1.4
105
|
L
 278.4%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
12.4
|
1.0
|
L
 -3.0%
H
1.0
1.0
|
L
 -6.8%
H
1.0
1.0
|
L
 5.5%
H
0.9
1.1
|
L
 -28.9%
H
0.8
1.4
|
L
 -73.8%
H
0.8
6.0
|
L
 -77.1%
H
0.7
9.7
|
L
 -92.9%
H
0.7
37.7
|
L
 -98.7%
H
0.7
135.5
|
| Moderna |
|
9,729.4
|
24.9
|
L
 -8.3%
H
24.7
26.6
|
L
 -6.8%
H
24.3
29.2
|
L
 -12.2%
H
24.3
29.5
|
L
 -9.8%
H
23.2
29.5
|
L
 -54.4%
H
23.2
56.7
|
L
 -83.2%
H
23.2
217.3
|
L
 -62.9%
H
23.2
497.5
|
L
H
11.5
497.5
|
| Mersana Therapeutics Inc |
|
47.1
|
9.4
|
L
 -1.5%
H
9.0
9.6
|
L
 -3.5%
H
9.0
10.6
|
L
 18%
H
7.8
11.2
|
L
 43.0%
H
5.2
11.2
|
L
 -79.3%
H
5.2
70.8
|
L
 -94.9%
H
5.2
240.5
|
L
 -98.0%
H
5.2
727.3
|
L
H
5.2
727.3
|
| Merus NV |
|
7,182.8
|
94.8
|
L
 -0.1%
H
94.8
94.9
|
L
 -0.1%
H
94.6
95.3
|
L
 0.7%
H
94.1
95.3
|
L
 44.6%
H
62.2
95.3
|
L
 88.4%
H
33.2
95.3
|
L
 365.1%
H
12.0
95.3
|
L
 731.4%
H
11.2
95.3
|
L
H
7.3
95.3
|
| Maravai LifeSciences Holdings |
|
425.4
|
2.9
|
L
 -6.4%
H
2.9
3.2
|
L
 -13.8%
H
2.9
3.5
|
L
 -1.0%
H
2.9
3.7
|
L
 32.4%
H
2.0
3.7
|
L
 -61.0%
H
1.7
8.3
|
L
 -80.9%
H
1.7
16.9
|
L
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
17.8
|
9.4
|
L
 -8.1%
H
9.3
12.5
|
L
 3.5%
H
8.6
12.5
|
L
 7.1%
H
8.3
12.5
|
L
 14.3%
H
7.6
12.5
|
L
 19.8%
H
7.5
16.5
|
L
 -54.8%
H
6.8
24.6
|
L
 -42.2%
H
6.8
49.1
|
L
 -66.4%
H
6.5
49.1
|
| MaxCyte Inc |
|
171.6
|
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 -1.2%
H
1.5
1.7
|
L
H
1.5
1.9
|
L
 -21.1%
H
1.3
2.2
|
L
 -57.3%
H
1.3
5.2
|
L
 -76.1%
H
1.3
7.4
|
L
 -1.2%
H
1.3
17.4
|
L
H
1.3
17.4
|
| QC Technologies Inc |
|
10.0
|
3.4
|
L
 -14.7%
H
3.4
4.0
|
L
 -19.6%
H
3.1
5.2
|
L
 -33.9%
H
3.1
7.0
|
L
 -66.6%
H
3.1
12.2
|
L
 -97.5%
H
3.1
164
|
L
 -100.0%
H
3.1
8940
|
L
 -99.9%
H
3.1
29850
|
L
 -100.0%
H
3.1
29850
|
| Mainz Biomed NV |
|
8.0
|
1.5
|
L
 -0.7%
H
1.4
1.5
|
L
 -7.6%
H
1.4
1.6
|
L
 -10.4%
H
1.3
1.8
|
L
 10.5%
H
1.3
1.9
|
L
 -83.8%
H
1.3
14.4
|
L
 -99.5%
H
1.3
384.5
|
L
H
1.3
1200
|
L
H
1.3
1200
|
| Mesoblast ADR |
|
2,066.8
|
16.1
|
L
 -3.3%
H
15.7
16.4
|
L
 -4.2%
H
15.7
17.0
|
L
 -5.4%
H
15.7
20.2
|
L
 6.2%
H
12.7
20.2
|
L
 90.0%
H
8.3
22
|
L
 459.4%
H
1.0
22
|
L
 48.5%
H
1.0
22
|
L
 35.0%
H
1.0
22
|
| Molecular Partners AG ADR |
|
152.6
|
4.1
|
L
 12.4%
H
3.8
4.7
|
L
 15.3%
H
3.5
4.7
|
L
 10.0%
H
3.5
4.7
|
L
 15.6%
H
3.5
4.8
|
L
 -33.3%
H
3.4
6.2
|
L
 -34.6%
H
3.3
12.7
|
L
 -79.9%
H
3.3
32.0
|
L
 -88.6%
H
3.3
38.8
|
| Mereo Biopharma Group Plc |
|
295.7
|
1.9
|
L
 -2.1%
H
1.8
1.9
|
L
 -7%
H
1.8
2.2
|
L
 -9.3%
H
1.8
2.3
|
L
 12.1%
H
1.5
2.3
|
L
 -56.5%
H
1.5
4.4
|
L
 109.0%
H
0.5
5.0
|
L
 -23.5%
H
0.3
5.0
|
L
H
0.3
8.5
|
| Natural Alternatives |
|
16.9
|
2.7
|
L
 0.4%
H
2.7
2.8
|
L
 0.4%
H
2.7
3
|
L
 -0.7%
H
2.6
3.1
|
L
 -24.4%
H
2.6
4.0
|
L
 -40%
H
2.6
4.8
|
L
 -67.9%
H
2.6
10.1
|
L
 -64.9%
H
2.6
19.9
|
L
 -53.3%
H
2.6
19.9
|
| NewAmsterdam Pharma Company NV |
|
4,167.3
|
37
|
L
 -2.5%
H
36.3
38.0
|
L
 3.6%
H
35.2
39.0
|
L
 20.5%
H
30.4
41.5
|
L
 73.9%
H
21.2
41.5
|
L
 120.8%
H
14.1
41.5
|
L
 268.5%
H
5.6
41.5
|
L
H
5.6
41.5
|
L
H
5.6
41.5
|
| Natures Sunshine Products |
|
242.7
|
13.8
|
L
 2.1%
H
13.2
13.8
|
L
 -2.4%
H
13.0
14.3
|
L
 -9.7%
H
13.0
15.8
|
L
 -12.9%
H
13.0
17.6
|
L
 5.0%
H
11.0
18.1
|
L
 64.2%
H
7.9
21.7
|
L
 30.4%
H
7.9
21.7
|
L
 16.5%
H
5.5
21.7
|
| Nautilus Biotechnology Inc |
|
233.7
|
1.9
|
L
 39.1%
H
1.3
1.9
|
L
 51.6%
H
1.2
1.9
|
L
 112.6%
H
0.8
1.9
|
L
 143.4%
H
0.6
1.9
|
L
 -29.1%
H
0.6
2.9
|
L
 -15.5%
H
0.6
4.7
|
L
 -82.0%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
14,154.2
|
142.0
|
L
 -0.9%
H
139.5
145.0
|
L
 -1.4%
H
133.6
150.0
|
L
 3.8%
H
133.6
150.0
|
L
 10.1%
H
123.7
150.0
|
L
 16.2%
H
84.2
154.6
|
L
 16.3%
H
84.2
158.0
|
L
 47.9%
H
71.9
158.0
|
L
 170.8%
H
31.3
158.0
|
| Minerva Neurosciences Inc |
|
26.7
|
3.8
|
L
 -9.1%
H
3.8
4.4
|
L
 -18.7%
H
3.8
4.8
|
L
 81.0%
H
2.1
12.5
|
L
 100%
H
1.8
12.5
|
L
 45.8%
H
1.2
12.5
|
L
 29.9%
H
1.2
13.5
|
L
 -84.6%
H
1.2
32.9
|
L
 -91.2%
H
1.2
126.7
|
| Nektar Therapeutics |
|
1,139.6
|
59.9
|
L
 -7.7%
H
57.3
64.0
|
L
 -0.3%
H
57.3
66.9
|
L
 -1.0%
H
52.9
66.9
|
L
 161.0%
H
21.6
66.9
|
L
 224.8%
H
6.5
66.9
|
L
 9.7%
H
6.2
66.9
|
L
 -75.2%
H
6.2
401.3
|
L
 -67.4%
H
6.2
1670.4
|
| Nkarta Inc |
|
147.0
|
2.1
|
L
 -1.9%
H
2.0
2.1
|
L
 -14.1%
H
2.0
2.4
|
L
 -5.5%
H
2.0
2.7
|
L
 -2.4%
H
1.9
2.7
|
L
 -34.9%
H
1.3
3.8
|
L
 -83.1%
H
1.3
16.2
|
L
 -92.9%
H
1.3
79.2
|
L
H
1.3
79.2
|
| NewcelX |
|
26.8
|
5.1
|
L
 -29.5%
H
5
5.9
|
L
 -60.5%
H
4.2
13.6
|
L
 -75.8%
H
4.2
21.3
|
L
 -71.4%
H
4.2
28.0
|
L
 -85.7%
H
4.2
47.4
|
L
 -97.9%
H
1.2
752
|
L
H
1.2
2940
|
L
H
1.2
2940
|
| MetaVia Inc |
|
24.2
|
1
|
L
 1.0%
H
1.0
1.0
|
L
 2.0%
H
1.0
1.0
|
L
 2.0%
H
0.9
1.2
|
L
 63.9%
H
0.6
1.7
|
L
 -62.6%
H
0.6
3.0
|
L
 -85.7%
H
0.4
7
|
L
 -99.4%
H
0.4
228.3
|
L
H
0.4
16192.5
|
| Nurix Therapeutics Inc |
|
1,279.3
|
12.6
|
L
 -2.5%
H
12.3
13.2
|
L
 13.8%
H
11.2
13.2
|
L
 39.0%
H
9.0
13.2
|
L
 14.3%
H
8.2
13.2
|
L
 -48.1%
H
8.2
29.6
|
L
H
4.2
29.6
|
L
 -49.8%
H
4.2
52.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics |
|
27.0
|
1.1
|
L
 -3.6%
H
1.1
1.1
|
L
 -8.5%
H
1.0
1.2
|
L
 -12.2%
H
1.0
1.3
|
L
H
1.0
2.0
|
L
 -15.0%
H
0.8
2.6
|
L
 -32.1%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharmaceuticals Inc |
|
67.7
|
2.9
|
L
 -8.1%
H
2.8
3.1
|
L
 -9.5%
H
2.8
3.4
|
L
 -14.4%
H
2.8
3.8
|
L
 10.0%
H
2.3
3.8
|
L
 106.5%
H
1.1
6.0
|
L
 -69.0%
H
1.1
54
|
L
 -97.4%
H
1.1
769.9
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,403.0
|
13.1
|
L
 3.6%
H
12.2
13.6
|
L
 -49.0%
H
11.6
16.8
|
L
 -36.1%
H
11.6
28.3
|
L
 13.8%
H
9.8
28.3
|
L
 -11.8%
H
5.9
28.3
|
L
 -74.4%
H
5.9
57.5
|
L
 -46.3%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc Ordinary Shares |
|
6,763.2
|
93.0
|
L
 -6.3%
H
92.4
99.8
|
L
 -0.4%
H
92.4
104.9
|
L
 10.9%
H
82
104.9
|
L
 19.6%
H
71.1
104.9
|
L
 4.3%
H
55.5
104.9
|
L
 198.7%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,284.8
|
7.9
|
L
 -5.8%
H
7.9
8.4
|
L
 -7.2%
H
7.9
8.8
|
L
 -17.2%
H
7.9
9.8
|
L
 20.6%
H
6.5
10.6
|
L
 -15.4%
H
5.0
11.6
|
L
 -61.4%
H
3.5
25.7
|
L
 -90.4%
H
3.5
331.7
|
L
 -94.9%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
161.9
|
6.4
|
L
 -5.2%
H
6.2
6.7
|
L
 2.6%
H
6.1
7
|
L
 4.8%
H
5.6
7
|
L
 -6.5%
H
5.6
7.4
|
L
 -8.4%
H
4.4
11.8
|
L
 -9.1%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
32.1
|
12.0
|
L
 -4.9%
H
11.2
12.5
|
L
 30.2%
H
8.5
13.2
|
L
 108.4%
H
5.8
13.2
|
L
 145.0%
H
4.8
13.2
|
L
 -24.9%
H
2.8
19.2
|
L
 -59.6%
H
2.8
30.8
|
L
 -89.9%
H
2.8
172.8
|
L
H
2.8
1308
|
| NuCana plc ADR |
|
7.5
|
3.9
|
L
 -1.8%
H
3.8
4.0
|
L
 -7.5%
H
3.7
4.4
|
L
 -14.9%
H
3.7
7.2
|
L
 -99.8%
H
2.8
2000
|
L
 -100.0%
H
2.8
66400
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
| Ocugen Inc |
|
480.9
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -4.4%
H
1.5
1.7
|
L
 -13.0%
H
1.5
1.9
|
L
 55.6%
H
0.9
1.9
|
L
 62.1%
H
0.5
1.9
|
L
 -3.1%
H
0.3
2.1
|
L
 450%
H
0.3
18.8
|
L
 -99.4%
H
0.2
293.4
|
| Oculis Holding AG |
|
1,019.5
|
19.5
|
L
 1.0%
H
19
20.1
|
L
 -8.3%
H
19
22.0
|
L
 11.5%
H
17.5
22
|
L
 10.1%
H
16
22
|
L
 9.0%
H
14
23.1
|
L
 95.0%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
| Ocular Therapeutix Inc |
|
2,417.8
|
11.4
|
L
 -2.1%
H
11.3
11.7
|
L
 -0.7%
H
11.3
12.1
|
L
 3.2%
H
10.9
12.5
|
L
 -4.3%
H
10.6
13.9
|
L
 9.8%
H
5.8
13.9
|
L
 221.4%
H
2
13.9
|
L
 7.5%
H
2
24.3
|
L
 18.2%
H
2
24.3
|
| Opus Genetics Inc |
|
128.2
|
2.1
|
L
 -7.0%
H
2.1
2.4
|
L
 7.5%
H
1.9
2.4
|
L
 18.9%
H
1.8
2.4
|
L
 100%
H
1.0
2.4
|
L
 82.9%
H
0.7
2.4
|
L
 -1.8%
H
0.7
6.6
|
L
 -70.8%
H
0.7
13.8
|
L
 -99.0%
H
0.7
340.8
|
| Insight Molecular Diagnostics |
|
175.2
|
6.1
|
L
 1.8%
H
5.8
6.2
|
L
 -7.7%
H
5.5
6.7
|
L
 83.2%
H
3.2
6.8
|
L
 139.1%
H
2.3
6.8
|
L
 104%
H
1.9
6.8
|
L
 -55.9%
H
1.9
14.0
|
L
 -79.2%
H
1.9
131.4
|
L
H
1.9
204.8
|
| OKYO Pharma Ordinary Shares |
|
101.5
|
2.7
|
L
 -1.5%
H
2.6
2.8
|
L
 13.0%
H
2.4
2.8
|
L
 36.4%
H
1.9
2.8
|
L
 -12.9%
H
1.9
3.4
|
L
 123.1%
H
0.9
3.4
|
L
 22.7%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharmaceuticals Inc |
|
577.9
|
8.4
|
L
 -6.1%
H
8.3
9.2
|
L
 4.9%
H
8.1
9.5
|
L
 -24.4%
H
6.7
11.5
|
L
 58.0%
H
4.5
11.5
|
L
 -28.4%
H
2.9
13.5
|
L
 128.2%
H
2.2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
| Omeros Corporation |
|
488.0
|
7.2
|
L
 -2.2%
H
7.1
7.4
|
L
 -5.0%
H
7.1
8.1
|
L
 69.9%
H
4.1
12.1
|
L
 98.6%
H
3.4
12.1
|
L
 75.7%
H
3.0
13.6
|
L
 110.9%
H
0.9
13.6
|
L
 -31.6%
H
0.9
23.9
|
L
 -48.0%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
113.9
|
1.1
|
L
 -8.4%
H
1.1
1.2
|
L
 -9.2%
H
1.1
1.3
|
L
 -23.2%
H
1.1
1.4
|
L
 10.1%
H
0.8
1.5
|
L
 -7.6%
H
0.3
1.5
|
L
 -16.2%
H
0.3
3.4
|
L
 -49.1%
H
0.3
4.8
|
L
 -66.8%
H
0.3
8.5
|
| Traws Pharma Inc |
|
17.0
|
2.4
|
L
 -7%
H
2.4
2.7
|
L
 -11.8%
H
2.4
3.1
|
L
 31.3%
H
1.8
3.3
|
L
 63.7%
H
1.3
3.3
|
L
 -52.1%
H
1.0
19.4
|
L
 -86.4%
H
1.0
37.3
|
L
 -97.5%
H
1.0
723.8
|
L
 -100.0%
H
1.0
106312.5
|
| VivoSim Labs Inc |
|
6.1
|
2.4
|
L
 -12.6%
H
2.4
2.7
|
L
 1.3%
H
2.1
3.2
|
L
 -31.8%
H
2.1
3.5
|
L
 27.6%
H
1.7
5.3
|
L
 -57.7%
H
0.3
22.0
|
L
 -87.5%
H
0.3
40.8
|
L
 -97.8%
H
0.3
287.0
|
L
 -99.7%
H
0.3
1197.6
|
| ORIC Pharmaceuticals Inc |
|
1,232.5
|
12.7
|
L
 -3.6%
H
12.3
13.4
|
L
 -3.1%
H
12.3
13.8
|
L
 12.1%
H
11.3
14.9
|
L
 25.4%
H
9.0
14.9
|
L
 34.7%
H
3.9
14.9
|
L
 375.3%
H
2.4
16.7
|
L
 -39.1%
H
2.4
40.8
|
L
H
2.4
40.8
|
| Oramed Pharmaceuticals Inc |
|
96.8
|
2.4
|
L
 -1.3%
H
2.3
2.4
|
L
 -1.3%
H
2.3
2.4
|
L
 -6.0%
H
2.2
2.6
|
L
 11.3%
H
2.0
2.7
|
L
 1.7%
H
1.8
3.1
|
L
 -64.6%
H
1.7
13.7
|
L
 -10.6%
H
1.7
31.5
|
L
 -65.6%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
57.7
|
1.3
|
L
 3.2%
H
1.2
1.3
|
L
 -6.5%
H
1.2
1.4
|
L
 21.5%
H
1.0
1.5
|
L
 -32.6%
H
0.8
3.0
|
L
 -78.5%
H
0.8
7.0
|
L
 -99.7%
H
0.8
812
|
L
 -99.6%
H
0.8
1704
|
L
H
0.8
17568
|
| Ovid Therapeutics Inc |
|
98.1
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 -15.3%
H
1.3
1.7
|
L
 -15.9%
H
1.3
2.0
|
L
 176%
H
0.5
2.0
|
L
 21.1%
H
0.2
2.0
|
L
 -17.9%
H
0.2
4.1
|
L
 -72.1%
H
0.2
7.0
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp |
|
1,757.9
|
43.4
|
L
 3.1%
H
40.0
44.4
|
L
 2.5%
H
40.0
44.4
|
L
 11.2%
H
35.8
44.4
|
L
 66.1%
H
26.1
44.4
|
L
 87.1%
H
16.2
44.4
|
L
 203.9%
H
9.4
44.4
|
L
 160.3%
H
9.4
44.4
|
L
 29.3%
H
9.4
54.6
|
| Palisade Bio Inc |
|
279.5
|
2
|
L
 -3.4%
H
1.8
2.0
|
L
 14.9%
H
1.6
2.1
|
L
 17.7%
H
1.5
2.3
|
L
 98.0%
H
0.5
2.3
|
L
 -27.8%
H
0.5
3.3
|
L
 -97.1%
H
0.4
128.1
|
L
 -99.9%
H
0.4
12015
|
L
 -100.0%
H
0.4
1485900
|
| Passage Bio Inc |
|
23.3
|
7.3
|
L
 -4.7%
H
7.2
7.9
|
L
 2.5%
H
6.8
7.9
|
L
 -9.1%
H
6.8
9
|
L
 27.5%
H
5.4
9
|
L
 -41.8%
H
5.1
26.6
|
L
 -70.7%
H
5.1
38.4
|
L
 -97.8%
H
5.1
617.4
|
L
H
5.1
764.6
|
| Paranovus Entertainment |
|
41.7
|
0.6
|
L
 3.3%
H
0.6
0.7
|
L
 1.6%
H
0.5
0.7
|
L
 -40.4%
H
0.5
1.2
|
L
 -31.1%
H
0.5
1.2
|
L
 -34.0%
H
0.5
1.5
|
L
 -74.2%
H
0.3
6.7
|
L
 -98.2%
H
0.3
51.6
|
L
H
0.3
122
|
| Puma Biotechnology Inc |
|
253.9
|
5.0
|
L
 -1.2%
H
5
5.2
|
L
 -3.6%
H
5
5.6
|
L
 -3.5%
H
4.9
5.8
|
L
 64.2%
H
3.0
6.1
|
L
 70.9%
H
2.3
6.1
|
L
 133.3%
H
2.1
7.7
|
L
 -35.2%
H
1.6
14.1
|
L
 -94.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
997.1
|
22.2
|
L
 3.8%
H
21.4
22.7
|
L
 2.1%
H
20.5
22.7
|
L
 -9.7%
H
19.8
25.3
|
L
 0.5%
H
19.8
27.6
|
L
 33.9%
H
16
27.6
|
L
 -56.5%
H
11.2
53.3
|
L
 -57.8%
H
11.2
82.2
|
L
 -57.4%
H
11.2
82.2
|
| Processa Pharmaceuticals Inc |
|
20.7
|
0.4
|
L
 -5.1%
H
0.4
0.4
|
L
 19.4%
H
0.3
0.4
|
L
 85%
H
0.2
0.6
|
L
 76.2%
H
0.2
0.6
|
L
 -67.8%
H
0.2
1.5
|
L
 -82.7%
H
0.2
5.9
|
L
 -91.1%
H
0.2
14.2
|
L
 -98.6%
H
0.2
35.9
|
| Vaxcyte Inc |
|
5,560.3
|
42.8
|
L
 -5.4%
H
42
46.0
|
L
 1.4%
H
42
46.0
|
L
 6.7%
H
40.3
46.0
|
L
 29.7%
H
29.1
46.0
|
L
 -59.7%
H
27.7
116
|
L
 0.7%
H
27.7
121.1
|
L
 15.6%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS Biotechnology Corporation |
|
43.4
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.2
|
L
 -8.8%
H
0.9
1.2
|
L
 -14.7%
H
0.9
1.5
|
L
 -71.8%
H
0.9
3.4
|
L
 -81.7%
H
0.9
13.7
|
L
 -55.1%
H
0.9
17.9
|
L
 -99.7%
H
0.6
384
|
| PepGen Inc |
|
311.4
|
4.5
|
L
 -2.8%
H
4.5
4.9
|
L
 -0.9%
H
4.4
5.7
|
L
 -10.8%
H
4.4
5.7
|
L
 243.2%
H
1.0
6.3
|
L
 -32.2%
H
0.9
7.5
|
L
 -58.0%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,468.1
|
4.2
|
L
 0.5%
H
4.0
4.4
|
L
 -3.9%
H
3.9
4.4
|
L
 24.9%
H
3.0
4.5
|
L
 149.1%
H
1.7
5.2
|
L
 413.6%
H
0.7
5.2
|
L
 153.7%
H
0.7
5.2
|
L
 -0.2%
H
0.7
11.1
|
L
 -88.3%
H
0.7
43.8
|
| Phathom Pharmaceuticals Inc |
|
976.7
|
13.7
|
L
 1.3%
H
13.2
14.1
|
L
 1.5%
H
13
16.1
|
L
 16.2%
H
10.3
16.1
|
L
 64.4%
H
8.0
16.1
|
L
 -24.9%
H
2.2
19.5
|
L
 33.3%
H
2.2
19.7
|
L
 -65.2%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Phio Pharmaceuticals Corp |
|
10.7
|
1.9
|
L
 -9.3%
H
1.7
4.2
|
L
 -12.3%
H
1.7
4.2
|
L
 -22.2%
H
1.7
4.2
|
L
 -20.2%
H
1.7
4.2
|
L
 -40.4%
H
1.0
9.8
|
L
 -97.1%
H
0.6
110.4
|
L
 -99.2%
H
0.6
470.9
|
L
 -100.0%
H
0.6
273240
|
| Pharvaris NV |
|
1,446.7
|
22.5
|
L
 1.3%
H
21.2
23.8
|
L
 -2.1%
H
21.2
23.8
|
L
 -2.9%
H
20.7
24.2
|
L
 12.5%
H
19.6
25.9
|
L
 -6.8%
H
11.5
26.3
|
L
 390.2%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
102.5
|
1.7
|
L
 -0.6%
H
1.6
1.7
|
L
 -7.7%
H
1.6
2.0
|
L
 11.3%
H
1.5
2.0
|
L
 5.7%
H
1.4
2.0
|
L
 -88.3%
H
1.1
16.1
|
L
 -93.2%
H
1.1
36.6
|
L
 -92.1%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
30.1
|
3.7
|
L
 -5.4%
H
3.6
4.0
|
L
 -5.4%
H
3.6
4.1
|
L
 -21.5%
H
3.6
4.9
|
L
 -28.5%
H
3.6
5.7
|
L
 -23.9%
H
3.3
7.1
|
L
 -38.5%
H
0.7
11.6
|
L
 -95.0%
H
0.7
94.8
|
L
 -97.3%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
6.3
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 -6.1%
H
0.9
1.0
|
L
 -8.9%
H
0.9
1.1
|
L
 -8%
H
0.8
1.3
|
L
 -49.7%
H
0.8
1.9
|
L
 -67.7%
H
0.8
3.2
|
L
 -92.4%
H
0.8
55.5
|
L
 -99.4%
H
0.8
253.4
|
| Praxis Precision Medicines Inc |
|
4,529.8
|
182.0
|
L
 -8.4%
H
167.0
186.7
|
L
 4.6%
H
167.0
206.7
|
L
 229.8%
H
50.3
206.7
|
L
 236.5%
H
37.2
206.7
|
L
 157.5%
H
26.7
206.7
|
L
 506.6%
H
11.9
206.7
|
L
 -63.8%
H
11.9
914.3
|
L
H
11.9
914.3
|
| PainReform |
|
2.3
|
1.2
|
L
 -6.5%
H
1.2
1.2
|
L
 -10.8%
H
1.2
1.3
|
L
 -14.7%
H
1.2
1.5
|
L
 -12.1%
H
1.2
3.6
|
L
 141.7%
H
0.4
16.6
|
L
 -96.8%
H
0.2
158.5
|
L
 -99.6%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
225.3
|
4.0
|
L
 150.3%
H
1.4
4.2
|
L
 145.7%
H
1.4
4.2
|
L
 176.4%
H
1.2
4.2
|
L
 379.5%
H
0.8
4.2
|
L
 206.2%
H
0.6
4.2
|
L
 -40.4%
H
0.6
8.7
|
L
 -88.6%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
812.9
|
4.6
|
L
 -7.7%
H
4.5
5.0
|
L
 -14.5%
H
4.3
5.2
|
L
 -31.6%
H
4.3
6.9
|
L
 12.9%
H
3.1
6.9
|
L
 14.3%
H
1.1
6.9
|
L
 -77.5%
H
1.1
21.7
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
387.5
|
2.9
|
L
 -6.9%
H
2.7
3.1
|
L
 -10.9%
H
2.7
3.5
|
L
 2.5%
H
2.7
3.5
|
L
 1.1%
H
2.1
3.6
|
L
 83.9%
H
0.5
7.1
|
L
 -72.8%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProPhase Labs Inc |
|
13.7
|
0.3
|
L
 -8.3%
H
0.3
0.4
|
L
 -15.4%
H
0.3
0.4
|
L
 -40%
H
0.3
0.7
|
L
H
0.3
0.7
|
L
 -84.6%
H
0.2
2.2
|
L
 -97.2%
H
0.2
12.7
|
L
 -96.0%
H
0.2
16.0
|
L
 -76.6%
H
0.2
16.0
|
| ProQR Therapeutics NV |
|
272.8
|
2.6
|
L
 -5.8%
H
2.5
2.8
|
L
 -11%
H
2.5
3
|
L
 15.1%
H
2.2
3.1
|
L
 24.5%
H
1.8
3.1
|
L
 -30.6%
H
1.1
4.2
|
L
 181.5%
H
0.9
4.6
|
L
 -38.3%
H
0.5
9.5
|
L
 -82.7%
H
0.5
24
|
| Prothena Corporation plc |
|
567.4
|
10.5
|
L
 -2.0%
H
10.4
11.2
|
L
 7.3%
H
10.0
11.7
|
L
 5.5%
H
9.6
11.7
|
L
 54.8%
H
6.7
11.7
|
L
 -36.7%
H
4.3
18.8
|
L
 -82.4%
H
4.3
79.7
|
L
 -4.4%
H
4.3
79.8
|
L
 -80.9%
H
4.3
79.8
|
| AlphaTON Capital Corp |
|
30.3
|
4.8
|
L
 -7.2%
H
4.6
5.1
|
L
 -7.0%
H
4.6
5.6
|
L
 -19.8%
H
4.6
13.8
|
L
 -12.0%
H
4.6
13.8
|
L
 -14.5%
H
3.0
15.8
|
L
 -96.6%
H
2.1
153.4
|
L
 -97.4%
H
2.1
899.5
|
L
 -98.3%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
51.6
|
0.5
|
L
 -3.7%
H
0.5
0.6
|
L
 -16.1%
H
0.5
0.6
|
L
 -23.5%
H
0.5
0.9
|
L
 -10.3%
H
0.4
0.9
|
L
 -61.5%
H
0.2
2.3
|
L
 -92.1%
H
0.2
7.5
|
L
 -98.5%
H
0.2
81.3
|
L
 -100.0%
H
0.2
46125
|
| PTC Therapeutics Inc |
|
5,396.2
|
67.9
|
L
 -0.6%
H
66.1
69.2
|
L
 2.3%
H
66
69.9
|
L
 7.8%
H
62.3
69.9
|
L
 30.3%
H
43.2
69.9
|
L
 67.9%
H
36.0
69.9
|
L
 84.6%
H
17.5
69.9
|
L
 23.5%
H
17.5
70.8
|
L
 145.8%
H
4.0
70.8
|
| Protagonist Therapeutics Inc |
|
4,724.9
|
76.0
|
L
 -3.4%
H
75.5
80.4
|
L
 1.5%
H
74.0
80.4
|
L
 16.9%
H
62.2
93.3
|
L
 41.1%
H
50.5
93.3
|
L
 62.4%
H
33.3
93.3
|
L
 838.8%
H
7.2
93.3
|
L
 289.5%
H
6.9
93.3
|
L
H
4.5
93.3
|
| Protagenic Therapeutics Inc |
|
4.3
|
2.3
|
L
 -12.5%
H
2.1
2.5
|
L
 -26.5%
H
2.1
3.1
|
L
 -31.8%
H
2.1
3.8
|
L
 -17.3%
H
2.1
6.2
|
L
 268.9%
H
0.2
14.3
|
L
 2.3%
H
0.2
14.3
|
L
 -51.1%
H
0.2
28
|
L
 -100.0%
H
0.2
2200044.7
|
| Pulmatrix Inc |
|
17.8
|
4.9
|
L
 -1.0%
H
4.8
5.0
|
L
 0.8%
H
4.8
5.0
|
L
 0.2%
H
4.4
5.5
|
L
 -8.4%
H
4.3
5.6
|
L
 129.1%
H
2
10.4
|
L
 40.2%
H
1.6
10.4
|
L
 -78.0%
H
1.6
60.8
|
L
 -99.4%
H
1.6
1396
|
| Polypid |
|
60.3
|
3.8
|
L
 -1.0%
H
3.8
3.9
|
L
 10.2%
H
3.4
3.9
|
L
 9.5%
H
3.1
3.9
|
L
 11.1%
H
3.1
3.9
|
L
 14.9%
H
2.3
3.9
|
L
 -85.6%
H
2.3
38.7
|
L
 -98.8%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
236.3
|
3.8
|
L
 7.0%
H
3.5
4.2
|
L
 10.1%
H
3.2
4.2
|
L
 69.3%
H
2.2
4.2
|
L
 246.4%
H
1.0
4.2
|
L
 1.3%
H
0.8
5.4
|
L
 138.1%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Group NV ADR |
|
912.6
|
13.3
|
L
 1.7%
H
13.0
13.4
|
L
 -2.1%
H
13.0
14.1
|
L
 -12.5%
H
13.0
16.3
|
L
 21.5%
H
11
17.1
|
L
 56.3%
H
7.3
17.1
|
L
 16.8%
H
6.7
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
| Purple Biotech ADR |
|
7.8
|
0.9
|
L
 10.3%
H
0.8
0.9
|
L
 45.8%
H
0.6
1.4
|
L
 50.9%
H
0.6
1.4
|
L
 -60.4%
H
0.5
2.4
|
L
 -72.3%
H
0.5
13.4
|
L
 -97.9%
H
0.5
47.4
|
L
 -98.9%
H
0.5
145
|
L
H
0.5
1390
|
| PureTech Health Plc ADR |
|
429.0
|
17.8
|
L
 -0.2%
H
17.4
17.9
|
L
 0.1%
H
17
17.9
|
L
 -5.7%
H
16.7
19.1
|
L
 -7.0%
H
14.5
19.8
|
L
 -14.8%
H
13.3
25.0
|
L
 -38.8%
H
13.3
38.9
|
L
H
13.3
65.9
|
L
H
13.3
65.9
|
| Qualigen Therapeutics Inc |
|
5.7
|
2.8
|
L
 -1.4%
H
2.8
2.9
|
L
 -22.8%
H
2.7
3.4
|
L
 -49.7%
H
2.7
6.0
|
L
 29.5%
H
1.6
8.8
|
L
 -42.9%
H
0.1
8.8
|
L
 -97.5%
H
0.1
118.8
|
L
 -99.9%
H
0.1
2330
|
L
 -100.0%
H
0.1
468750
|
| Qilian International Holding |
|
1,932.0
|
9.6
|
L
 1.8%
H
9.5
9.7
|
L
 3.1%
H
9.0
9.7
|
L
 -5.4%
H
8.8
10.6
|
L
 12.0%
H
7
11.8
|
L
 34.7%
H
6.2
17.2
|
L
 72.0%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
| Quince Therapeutics Inc |
|
87.6
|
1.6
|
L
 -1.2%
H
1.6
1.7
|
L
 -7.4%
H
1.6
1.9
|
L
 -0.6%
H
1.6
2.2
|
L
 -3.0%
H
1.5
2.2
|
L
 3.8%
H
0.7
2.5
|
L
 79.1%
H
0.5
2.5
|
L
 -96.3%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
2,112.4
|
34.3
|
L
 -49.3%
H
22.9
36.2
|
L
 -43.8%
H
22.9
71.5
|
L
 -37.1%
H
22.9
71.5
|
L
 150.3%
H
12.9
71.5
|
L
 485.2%
H
5.4
71.5
|
L
 69.7%
H
3.7
71.5
|
L
 -16.1%
H
3.7
71.5
|
L
 82.6%
H
3.7
82.5
|
| Quoin Pharmaceuticals ADR |
|
6.2
|
10.3
|
L
 -8.6%
H
10.1
11.8
|
L
 -20.2%
H
10.1
13.6
|
L
 41.5%
H
7.1
41.8
|
L
 51.5%
H
6.6
41.8
|
L
 -98.0%
H
5.1
966
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
194.2
|
5.3
|
L
 1.5%
H
5.0
5.6
|
L
 -9.6%
H
5.0
6.9
|
L
 6.2%
H
4.6
6.9
|
L
 40.5%
H
3.1
7
|
L
 341.3%
H
1.4
9.2
|
L
 -9.5%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
209.7
|
2.2
|
L
 -2.3%
H
2
2.6
|
L
 18.1%
H
1.4
2.6
|
L
 330%
H
0.4
3.9
|
L
 305.7%
H
0.4
3.9
|
L
 -6.9%
H
0.4
3.9
|
L
 -66.3%
H
0.4
9.0
|
L
 -99.0%
H
0.4
36.3
|
L
H
0.4
224.5
|
| RAPT Therapeutics Inc |
|
730.0
|
29.4
|
L
 -2.9%
H
29.0
31.6
|
L
 -0.6%
H
29.0
31.6
|
L
 0.9%
H
24.3
42.4
|
L
 179.8%
H
8.8
42.4
|
L
 64.5%
H
5.7
42.4
|
L
 -83.1%
H
5.7
251.6
|
L
 -87.4%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
3,225.6
|
33.5
|
L
 -3.3%
H
32.9
35.0
|
L
 -0.2%
H
32.9
36.0
|
L
 8.3%
H
29.6
36.0
|
L
 17.7%
H
26.5
36.0
|
L
 -34.4%
H
25.8
53.5
|
L
 -17.5%
H
25.8
60.4
|
L
 -65.0%
H
25.8
179.7
|
L
 -69.5%
H
25.8
179.7
|
| Rocket Pharmaceuticals Inc |
|
384.1
|
3.6
|
L
 -5.6%
H
3.4
3.9
|
L
 -7.5%
H
3.4
4.1
|
L
 10.9%
H
3.1
4.5
|
L
 19.1%
H
2.8
4.5
|
L
 -79.0%
H
2.2
18.2
|
L
 -80.3%
H
2.2
32.5
|
L
 -87.6%
H
2.2
67.5
|
L
 -92.0%
H
2.2
67.5
|
| Regeneron Pharma |
|
67,500.1
|
642.3
|
L
 -1.5%
H
627.5
657.5
|
L
 11.1%
H
575.9
664
|
L
 7.0%
H
541
664
|
L
 14.9%
H
541
664
|
L
 -23.9%
H
476.5
852
|
L
 -13.3%
H
476.5
1211.2
|
L
 17.1%
H
441
1211.2
|
L
 10.9%
H
271.4
1211.2
|
| Replimune Group Inc |
|
725.9
|
9.3
|
L
 -4.4%
H
8.3
9.6
|
L
 5.7%
H
8.3
10.9
|
L
 100%
H
4.3
10.9
|
L
 22.4%
H
3.1
10.9
|
L
 -21.9%
H
2.7
17
|
L
 -51.6%
H
2.7
29.5
|
L
 -77.9%
H
2.7
54.9
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
2.8
|
1.2
|
L
 -4%
H
1.2
1.3
|
L
 -5.5%
H
1.2
1.4
|
L
 -21.6%
H
1.2
1.7
|
L
 -50.8%
H
1.2
2.9
|
L
 -97.0%
H
0.7
60.5
|
L
 -100.0%
H
0.7
16405.2
|
L
H
0.7
569016
|
L
H
0.7
569016
|
| Regencell Bioscience Holdings |
|
6,705.3
|
13.6
|
L
 -18.6%
H
13.6
16.9
|
L
 -14.7%
H
13.6
17.5
|
L
 -16.0%
H
13.6
21.8
|
L
 4.6%
H
12.0
21.8
|
L
 6357.1%
H
0.1
83.6
|
L
 1923.9%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,448.2
|
150.2
|
L
 0.7%
H
146.4
150.8
|
L
 -9.7%
H
144.2
168.0
|
L
 3.4%
H
143.5
169.9
|
L
 26.3%
H
110.8
169.9
|
L
 8.3%
H
103.0
182.5
|
L
 -12.4%
H
103.0
212.2
|
L
 -11.7%
H
103.0
327.3
|
L
 335.1%
H
20.1
327.3
|
| Regenxbio Inc |
|
605.7
|
12.0
|
L
 -6.1%
H
11.5
12.5
|
L
 -8.0%
H
11.5
13.9
|
L
 13.3%
H
10.2
13.9
|
L
 46.4%
H
7.4
13.9
|
L
 36.4%
H
5.0
13.9
|
L
 -50.5%
H
5.0
28.8
|
L
 -57.1%
H
5.0
50.3
|
L
 -27.1%
H
5.0
85.1
|
| Rigel Pharmaceuticals |
|
549.8
|
30.7
|
L
 -2.9%
H
29.6
31.7
|
L
 2.3%
H
29.1
32.9
|
L
 9%
H
26.4
32.9
|
L
 39.9%
H
21.8
43.7
|
L
 115.9%
H
13.9
43.7
|
L
 4278.6%
H
0.7
43.7
|
L
 1126%
H
0.6
43.7
|
L
 990.7%
H
0.6
43.7
|
| Relay Therapeutics Inc |
|
1,196.5
|
6.9
|
L
 -2.8%
H
6.6
7.3
|
L
 1.2%
H
6.6
7.6
|
L
 33.0%
H
5.3
7.6
|
L
 106.6%
H
3.0
7.6
|
L
 19.7%
H
1.8
7.6
|
L
 -67.6%
H
1.8
23.2
|
L
 -80.6%
H
1.8
64.4
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
73.0
|
2.2
|
L
 -2.7%
H
2.2
2.3
|
L
 4.8%
H
2.2
2.6
|
L
 -17.3%
H
1.8
2.8
|
L
 272.9%
H
0.6
2.8
|
L
 -37.0%
H
0.2
3.7
|
L
 -65.5%
H
0.2
7.2
|
L
 -92.6%
H
0.2
40
|
L
 -84.9%
H
0.2
54
|
| Avidity Biosciences Inc |
|
10,254.4
|
69.8
|
L
 -0.1%
H
69.8
69.9
|
L
 42.0%
H
69.5
70.5
|
L
 58.0%
H
44.3
70.5
|
L
 94.3%
H
34.9
70.5
|
L
 66.7%
H
21.5
70.5
|
L
 392.2%
H
4.8
70.5
|
L
 166.5%
H
4.8
70.5
|
L
H
4.8
70.5
|
| TransCode Therapeutics Inc |
|
9.6
|
10.5
|
L
 -6.2%
H
10.5
11.1
|
L
 -21.5%
H
10.5
14.0
|
L
 -0.7%
H
10.3
21.0
|
L
 -8.6%
H
9.3
21.0
|
L
 -97.6%
H
6.2
505.0
|
L
 -100.0%
H
6.2
864864
|
L
H
6.2
5174400
|
L
H
6.2
5174400
|
| RenovoRx Inc |
|
39.9
|
1.1
|
L
 -1.8%
H
1.1
1.1
|
L
 -7.6%
H
1.0
1.2
|
L
 -14.2%
H
1.0
1.4
|
L
 -9.9%
H
0.8
1.5
|
L
 6.9%
H
0.8
1.7
|
L
 -38.1%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences |
|
13,384.5
|
19.6
|
L
 -2.0%
H
19.3
20.0
|
L
 7.6%
H
18.3
20.1
|
L
 22.7%
H
15.3
20.1
|
L
 73.3%
H
10.9
20.1
|
L
 67.8%
H
8.7
20.1
|
L
 283.6%
H
4.7
20.1
|
L
H
2.5
20.1
|
L
H
2.5
20.1
|
| Royalty Pharma plc Ordinary |
|
16,124.5
|
37.3
|
L
 -0.6%
H
37.1
37.7
|
L
 0.1%
H
35.9
37.7
|
L
 2.2%
H
35.2
37.7
|
L
 0.5%
H
34.1
38
|
L
 37.6%
H
24.1
38
|
L
 -11.8%
H
24.1
44.5
|
L
 -0.7%
H
24.1
53.2
|
L
H
24.1
56.5
|
| Repare Therapeutics Inc |
|
79.0
|
1.8
|
L
H
1.8
1.9
|
L
 -6.1%
H
1.7
1.9
|
L
H
1.7
2.0
|
L
 22.7%
H
1.5
2.0
|
L
 -45.1%
H
0.9
4.1
|
L
 -87.6%
H
0.9
18.7
|
L
 -93.0%
H
0.9
46.4
|
L
H
0.9
46.4
|
| Revolution Medicines Inc |
|
11,090.7
|
59.3
|
L
 0.8%
H
56.7
59.4
|
L
 8.9%
H
55.4
60.1
|
L
 29.8%
H
45.7
60.1
|
L
 62.0%
H
34
60.1
|
L
 7.7%
H
29.2
62.4
|
L
 190.0%
H
15.5
62.4
|
L
 92.8%
H
14.1
62.4
|
L
H
14.1
62.4
|
| Reviva Pharmaceuticals |
|
56.8
|
0.6
|
L
 -1.7%
H
0.6
0.7
|
L
 -13.2%
H
0.6
0.7
|
L
 20.4%
H
0.4
0.9
|
L
 34.1%
H
0.3
0.9
|
L
 -41.6%
H
0.3
4.3
|
L
 -86.1%
H
0.3
9.3
|
L
 -94.6%
H
0.3
15.1
|
L
H
0.3
15.1
|
| Recursion Pharmaceuticals Inc |
|
2,374.8
|
5.4
|
L
 -1.5%
H
5.3
5.8
|
L
 -9.9%
H
5.3
6.5
|
L
 -1.5%
H
5.1
7.2
|
L
 -4.2%
H
4.5
7.2
|
L
 -15%
H
3.8
12.4
|
L
 -47.5%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharmaceuticals Inc |
|
7,554.6
|
113.7
|
L
 0.0%
H
110.0
114.2
|
L
 3.0%
H
108.6
116
|
L
 17.0%
H
96.3
116
|
L
 28.8%
H
85.7
116
|
L
 132.1%
H
45.9
116
|
L
 396.7%
H
15.5
116
|
L
 426.8%
H
3.0
116
|
L
H
3.0
116
|
| Rezolute Inc |
|
826.5
|
9.1
|
L
 -2.4%
H
9.0
9.5
|
L
 -1.0%
H
9.0
10.0
|
L
 -1.0%
H
7.8
10.0
|
L
 55.0%
H
5.5
10.0
|
L
 65.5%
H
2.2
10.0
|
L
 448.2%
H
0.7
10.0
|
L
 -48%
H
0.7
21.1
|
L
 -85.6%
H
0.7
100
|
| Redhill Biopharma ADR |
|
4.2
|
1.3
|
L
 -2.3%
H
1.3
1.4
|
L
 -22.6%
H
1.3
1.7
|
L
 -42.8%
H
1.3
2.3
|
L
 5.8%
H
1.1
2.8
|
L
 -84.5%
H
1.1
8.8
|
L
 -99.8%
H
1.1
650
|
L
 -100.0%
H
1.1
11520
|
L
 -100.0%
H
1.1
16540
|
| SAB Biotherapeutics Inc |
|
33.8
|
3.3
|
L
H
3.1
3.3
|
L
 7.3%
H
2.9
3.3
|
L
 61.7%
H
2.0
3.3
|
L
 45.7%
H
1.9
3.3
|
L
 -4.4%
H
1
6.6
|
L
 242.1%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana Biotechnology Inc |
|
1,175.6
|
4.6
|
L
 -7.7%
H
4.5
5
|
L
 -18.3%
H
4.5
5.7
|
L
 15.1%
H
3.9
6.6
|
L
 16.9%
H
2.8
6.6
|
L
 24.9%
H
1.3
7.3
|
L
 -21.3%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
154.1
|
3.2
|
L
 -2.2%
H
3.0
3.3
|
L
 -15.6%
H
3.0
3.9
|
L
 -7%
H
3.0
5.0
|
L
 50.5%
H
2.0
5.0
|
L
 -87.8%
H
1.2
34.0
|
L
 -91.1%
H
1.2
45.4
|
L
 -64.3%
H
1.2
146.2
|
L
 -75.6%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
8.4
|
1.7
|
L
 -3.4%
H
1.6
1.8
|
L
 -12.3%
H
1.6
2.1
|
L
 13.3%
H
1.5
2.4
|
L
 21.3%
H
1.4
2.4
|
L
 -39.8%
H
1.2
3.9
|
L
 -97.9%
H
0.1
140
|
L
 -99.5%
H
0.1
6280
|
L
 -100.0%
H
0.1
300000
|
| Scilex Holding Company |
|
132.3
|
17.9
|
L
 8.2%
H
16.2
18.0
|
L
 9.5%
H
16.1
20.0
|
L
 2.9%
H
12.6
20.0
|
L
 33.2%
H
12.6
34.3
|
L
 1722.5%
H
0.2
34.3
|
L
 71.4%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
26.8
|
0.6
|
L
 -3.0%
H
0.6
0.7
|
L
 -16.9%
H
0.6
0.8
|
L
 -20%
H
0.6
0.9
|
L
 -5.9%
H
0.6
1.3
|
L
 -52.2%
H
0.6
1.5
|
L
 -70.9%
H
0.6
3.9
|
L
 -85.7%
H
0.6
10.3
|
L
 -99.0%
H
0.6
76.9
|
| Seer Inc Ordinary Shares |
|
127.9
|
2.3
|
L
 2.7%
H
2.2
2.3
|
L
 -1.7%
H
2.2
2.4
|
L
 2.7%
H
2.1
2.4
|
L
 6.6%
H
2.0
2.4
|
L
 19.5%
H
1.6
2.6
|
L
 -69.3%
H
1.5
8.7
|
L
H
1.5
86.6
|
L
H
1.5
86.6
|
| Sangamo Therapeutics Inc |
|
175.0
|
0.6
|
L
 -3.3%
H
0.6
0.6
|
L
 -7.9%
H
0.6
0.7
|
L
 -17.1%
H
0.6
0.8
|
L
 3.6%
H
0.4
0.8
|
L
 -69.2%
H
0.4
3.2
|
L
 -86.4%
H
0.3
4.3
|
L
 -94.4%
H
0.3
19.4
|
L
 -92.6%
H
0.3
27.5
|